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Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a serious debilitating condition 
that can be cured by pulmonary endarterectomy (PEA) surgery. Despite having effective 
treatment, a significant proportion of CTEPH patients do not undergo PEA surgery. There is 
limited information in the existing literature on the impact of these treatment decisions by the 
patients on their long-term survival. 
This research retrospectively examines a large, contemporary cohort of consecutive, newly 
diagnosed, treatment-naïve patients with chronic thromboembolic pulmonary hypertension 
(CTEPH) who were identified from the ASPIRE (Assessing the Spectrum of Pulmonary 
hypertension at a Referral centre) registry database. It compares the clinical course of different 
sub-groups of patients with CTEPH, with a focus on patients with technically operable disease 
who have not undergone surgery. I have described the baseline characteristics, investigations, 
and treatment received by the patients. I have also identified prognostic factors in different sub-
groups of patients with CTEPH and compared their long-term survival following treatment. 
In this study I have demonstrated that survival is better following PEA as compared to patients 
with technically operable disease not undergoing surgery as well as patients with a non-surgical 
disease distribution. I found that patients deemed unfit for surgery had a worse survival rate 
than patients who were offered surgery but declined, who in turn had a worse survival rate than 
patients presenting with other contributors to symptoms in addition to clot burden.  
I also identified risk factors in patients that contributed to poor prognosis which might be useful 
in counselling patients and aid in clinical decision-making. Finally, I have shown that a non-
invasive multimodal imaging approach can be helpful in PEA operability assessment in patients 




Plain Language Summary 
Chronic thromboembolic pulmonary hypertension (CTEPH) occurs when blood clots in the lungs 
do not resolve. This causes the pressure in the lungs to rise. Without treatment CTEPH is a 
serious condition which significantly reduces life expectancy of the sufferer. CTEPH occurs in 
approximately 1 in 20 patients who have had a lung clot (also known as a pulmonary 
embolism). The condition is curable by a surgical procedure called pulmonary endarterectomy 
where the chronic lung clots are removed. However, not all patients are suitable for the 
operation and some patients who are suitable for the operation decline surgery. This study 
identifies several laboratory tests that can be used to identify patients at highest risk of poor 
prognosis and shows that surgery provides very good long-term results with respect to the 
survival rates of the patients. The findings of this study will help doctors better engage with 
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Chapter 1. Chronic thromboembolic 







Pulmonary hypertension (PH) is defined as a mean pulmonary artery pressure (mPAP) ≥25 
mmHg at rest, measured during right heart catheterization and is classified into five groups 
(table 1) (Galie et al., 2015). Group 1, also known as Pulmonary Arterial Hypertension (PAH) 
includes a cluster of conditions that share similar pathophysiology that can be treated with PAH 
specific targeted therapy (McGoon and Miller, 2012). Group 2 (Pulmonary Hypertension due to 
left heart disease), Group 3 (Pulmonary Hypertension due to lung diseases and or hypoxemia) 
and Group 5 (PH with unclear multifactorial mechanism) are more common than PAH, with 
treatment aimed at dealing with the underlying conditions (Galie et al., 2015).  
The current study focuses on Group 4 PH. Also called chronic thromboembolic pulmonary 
hypertension (CTEPH), it is a severe but potentially curable form of pulmonary hypertension 
(Kim et al., 2013). It may follow an acute episode of pulmonary embolism (Lang et al., 2013, 
Pepke-Zaba et al., 2013a) but can also present as unexplained PH with no previous history of 
venous thromboembolism (Humbert M, 2010, Hoeper et al., 2006, Lang, 2004). Over the past 
20 years the treatment of CTEPH has evolved significantly. Current protocols now include 
Pulmonary Endarterectomy (PEA) in operable cases (Jamieson SW, 2003) and PH specific 
therapy for inoperable disease (Simonneau et al., 2016, Jais et al., 2008, Suntharalingam et al., 
2008, Reichenberger et al., 2007, Ghofrani et al., 2013, Simonneau, 2013, Simonneau, 2014). 
Balloon pulmonary angioplasty has also been considered as a potential alternative to surgery in 
selected patients (Mizoguchi et al., 2012, Feinstein et al., 2001, Inami et al., 2016, Galie et al., 
2015). 
Pulmonary endartarectomy (PEA) is the treatment of choice in CTEPH patients with operable 
disease with excellent symptomatic benefit and long term survival (Bonderman et al., 2007, 
Galie et al., 2015, Konstantinides, 2014). Analyses of large registries have shown a 10 year 
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survival of 72-75% in operated patients (Cannon et al., 2016, Madani et al., 2012). In contrast, 
treatment with anticoagulation alone in patients with mPAP of above 50 mmHg was found to 
result in a 5 year survival of only 10% (Lewczuk et al., 2001, Riedel M, 1982). PH specific 
targeted therapy with riociguat, a soluble guanylate cyclase stimulator (sGCs), has recently 
been licensed for the treatment of inoperable CTEPH disease in the UK. A recent Randomised 
controlled trial showed that patients with inoperable disease due or persistent PH post PEA had 
improved pulmonary haemodynamics and exercise capacity following pulmonary vasodilator 
therapy with riociguat with a 2 year survival of 93% (Ghofrani et al., 2013, Simonneau, 2013, 
Simonneau, 2014, Simonneau et al., 2016). The MERIT-1 trial examining the effects of 
macitentan versus placebo in patients with inoperable CTEPH have shown a decrease in PVR 
(at 16 week follow-up) and improvement in exercise capacity (at 24 week follow-up) (Ghofrani et 
al., 2017). 
Despite excellent outcomes following surgery, a significant proportion of patients who have 
technically operable disease choose to not undergo surgery for a variety of reasons (Condliffe 
et al., 2008, Delcroix et al., 2016, Hurdman et al., 2012, Pepke-Zaba et al., 2011, Mayer et al., 
2011, Escribano-Subias et al., 2016, Bunclark, 2017). To date only limited data exists on the 
clinical course of patients who have technically operable disease and do not undergo surgery.  
In this thesis I have reviewed our current understanding of CTEPH and presented the predictors 
of mortality and long-term outcomes in a large cohort of patients with CTEPH. Furthermore, 
utilising the data on characteristics of patients with technically operable CTEPH who do not 
undergo surgery I have been able to identify prognostic factors that has the potential to inform 






Definition of CTEPH 
As per the most recent guidelines, for a diagnosis of CTEPH to be made, a patient needs to 
have an mPAP of ≥25 mm Hg and at least one (segmental) perfusion defect detected by 
perfusion lung scan or evidence of obstructions seen at CT angiography or conventional 
pulmonary angiography. Furthermore, patients should have received at least 3 months of 
effective anticoagulation. This is in order to discriminate this condition from ‘sub-acute’ 
Pulmonary embolism (PE). (Konstantinides, 2014, Kim, 2018b). 
Classification of CTEPH 
Thistlethwaite and co-workers have classified CTEPH into four types based on the intra-
operative location of the thrombotic material. Type 1 (fresh thrombus in main-lobar pulmonary 
arteries); type 2 (intimal thickening and fibrosis proximal to the segmental arteries); type 3 
(disease within distal segmental arteries only); and type 4 (distal arteriolar vasculopathy without 
visible thromboembolic disease). Disease types can also be grouped into proximal (type 1 and 
2) and distal disease (type 3 and 4). It has been seen that patients diagnosed with proximal type 
disease at PEA have a better prognosis as compared to patients with distal type disease 
(Thistlethwaite et al., 2002).  
CTEPH can also be classified pre-operatively utilising imaging techniques. They are grouped 
into proximal and distal disease by the distribution of obstructions in the pulmonary vasculature. 
Proximal CTEPH involves main, lobar, and segmental pulmonary arteries and is also termed 
operable disease. Distal CTEPH involves sub segmental or smaller pulmonary arteries and is 
termed in-operable disease as it is usually surgically inaccessible (Cannon JE, 2013). The 







Pathophysiology of CTEPH 
 
Pulmonary arterial obstruction followed by pulmonary vascular remodelling is considered to be 
the primary contributor in the development of CTEPH. However, the pathogenesis of CTEPH 
has been found to be multifactorial. Research done on the subject implicate factors such as 
infection, abnormal immune responses and fibrinolysis, genetics and inflammation in the 
development of this condition (Galie et al., 2015, Satoh et al., 2017, Toshner, 2016, Planquette 
et al., 2018, Wilkens et al., 2018). The current understanding of the mechanisms leading to the 
development of CTEPH are shown in figure 1. 
There are 2 main hypotheses regarding the aetiology of CTEPH. As per the ‘embolic 
hypothesis’, CTEPH is thought to occur as a consequence of a failure in clot resolution following 
an acute pulmonary embolism. The resulting fibrosis within the clot causing pulmonary vascular 
remodelling and secondary small vessel disease. This eventually leads to the development of 
pulmonary hypertension and right ventricular dysfunction (Humbert M, 2010). Thus, the embolic 
hypothesis is also called the ‘two compartment model’ (Moser and Braunwald, 1973).  
An alternative to the ‘embolic hypothesis’ is the ‘thrombotic hypothesis’. This hypothesis states 
that an arteriopathy with accompanying endothelial cell dysfunction and in-situ thrombosis 
resulting in pulmonary vascular occlusions is the primary process by which CTEPH occurs. 
These arteriopathies in turn perpetuate pulmonary vascular remodelling leading to the 
development of PH (Humbert M, 2010). However, the causal aetiology of CTEPH might be 
heterogeneous, with the embolic hypothesis the major contributor in patients with more proximal 
and surgical disease, while the thrombotic hypothesis may be more important in patients with 
distal and non-surgical disease. 
Studies have also suggested that inflammation might have an important role to play in the 
development of the disease (Hassoun et al., 2009).  Quark et al. found high plasma levels of 
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inflammatory mediators including CRP, IL-10, MCP-1, MIP-1α and MMP-9 in patients with 
CTEPH confirming its role in the development of the condition (Quarck et al., 2015). Zabini et al. 
similarly reported raised levels of inflammatory cytokines such as serum IP-10 in patients with 
CTEPH and IPAH. They also found an association between high serum IP-10 levels and poor 
pulmonary haemodynamics and exercise capacity in patients suffering from CTEPH (Zabini et 
al., 2014). Soon et al. found that high serum levels of inflammatory cytokines like IL-6 and IL-8 
in patients with CTEPH could predict the risk of developing persistent PH post PEA (Soon et al., 
2010). Langer and co-workers found that high cytokine levels such as TNF alpha in patients 
with CTEPH significantly fell within 24 hours after PEA surgery, thus suggesting a potential role 
in the development of the disease (Langer et al., 2004). It has been reported that merely having 
PH post PEA surgery does not significantly affect long-term outcome (Condliffe et al., 2009). 
However, more recent studies have suggested that significant residual PH is associated with a 
worse outcome (Delcroix et al., 2016) (Cannon et al., 2016). Rose and co-workers found 
increased production of mediators of neutrophil function in patients with CTEPH and IPAH. 
These were reduced by nebulised iloprost and was reflected clinically as an improvement in the 
pulmonary haemodynamics in both patient groups (Rose et al., 2003).  
Although the role on inflammation in the development of CTEPH has been established by 
current research whether targeting inflammation is important in the treatment of established 
CTEPH or acute pulmonary embolism is currently unknown. Given that PEA can potentially cure 
CTEPH in selected patients, it can be surmised that for patients with established proximal 
surgical disease targeting inflammation might be of limited value. 
Incidence & Prevalence of CTEPH 
The exact incidence and prevalence of CTEPH is still largely unknown, although over the recent 
years there has been an increasing number of epidemiological studies exploring the subject. 
The UK audit provides a unique country-wide source of information on the relative prevalence of 
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CTEPH in different parts of the UK (GIBBS S et al., 2011). Analysis of an international registry 
by Pepke-Zaba et al. in 2013 reported an incidence of 5 per million of population per year in the 
UK (Pepke-Zaba et al., 2013b). However, approaches that target particular populations may 
increase diagnostic rates. De-Fonseka and co-workers showed that the annual incidence of 
CTEPH was 15 cases/million/year in the Sheffield city population. The Sheffield data included 
patients diagnosed through a dedicated PE clinic and those presenting with unexplained PH 
(De-Fonseka D, 2014). A recent report from Bath (UK) which was generated by developing a 
regional specialist PH service showed an incidence of CTEPH of 8.3 per million of population 
per year in that region (Suntharalingam, 2018).  
Associated risk factors and prognostic indicators in CTEPH 
CTEPH has been found to be associated with a variety of medical conditions, with some factors 
have prognostic significance. Incomplete resolution of clots has frequently been observed after 
an acute pulmonary embolus. The degree of obstruction to the pulmonary vasculature is low in 
most of the cases (Miniati et al., 2006, Planquette et al., 2018). A recent report from Switzerland 
suggested that the cumulative incidence of CTEPH two years after an acute PE could be as low 
as 0.79% (Coquoz et al., 2018). However, Pengo et al. found that the cumulative risk of 
developing CTEPH was 3.8% within 2 years after an acute PE (Pengo et al., 2004). Pepke-
Zaba and co-workers showed that a history of VTE was the greatest risk factor in the 
development of CTEPH and was present in approximately 75% of patients. They found that 
thrombophilic disorders and family history of VTE were more common in patients who were 
considered operable. On the other hand, splenectomy, major surgery, CCF, and a history of 
cancer were more common in the non-operable group (Pepke-Zaba et al., 2011). Lang and co-
workers found that risk factors for CTEPH included a history of acute VTE, large clot burden on 
imaging, non-O blood groups, and older age. In addition, they found that operability in patients 
with CTEPH was associated with younger age, proximal clots, and lower pulmonary vascular 
resistance (Lang et al., 2013). Condliffe et al. also found that a history of VTE was more 
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common in operable patients and previous history of splenectomy was more common in non-
operable patients. Interestingly, they reported that associated medical conditions such as 
previous pacemaker lead, atrio-ventricular shunt, splenectomy and inflammatory bowel disease 
did not affect survival (Condliffe et al., 2009).  
The pulmonary vascular resistance before PEA has also been found to be directly proportional 
to the perioperative mortality (Dartevelle et al., 2004). Jamieson and co-workers found that 
preoperative PVR was the largest risk factor for surgery and postoperative PVR was an 
important indicator of mortality in patients with CTEPH  (Jamieson SW, 2003). A 2018 report 
from France showed that pre-operative PVR was a significant independent predictor of 
postoperative as well as three-year mortality (Tromeur et al., 2018). The international CTEPH 
registry showed that functional class IV, increased RAP, history of cancer and dialysis-
dependent renal failure was associated with higher mortality in operated and non-operated 
patients. For operated patients, bridging therapy, persistent PH post-PEA, surgical 
complications post-PEA and additional cardiac procedures was associated with higher mortality 
rates. On the other hand, co-morbidities such as coronary artery disease, COPD and left heart 
failure were also associated with higher mortality in non-operated patients. However, a history 
of VTE and higher preoperative mPAP was found to be associated with a lower perioperative 
mortality. (Delcroix et al., 2016). Recent registry data from Europe suggested that the 
independent predictors of survival in patients with CTEPH (who did not undergo PEA surgery) 
and patients with persistent PH post PEA surgery who were treated with PH specific targeted 
therapy were WHO functional class and BNP/NT-pro BNP (Delcroix et al., 2018). Figure 2 is a 
diagrammatic representation of some of the known risk factors for CTEPH. 
Clinical presentation of CTEPH 
The clinical features of CTEPH are non-specific and are similar to the other forms of PH. 
Patients may be asymptomatic, particularly if their exercise capacity is limited by other 
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comorbidities. In the international CTEPH registry the commonest symptoms included dyspnoea 
(99%), oedema (41%), fatigue (32%), chest pain (15%) and syncope (14%) (Pepke-Zaba et al., 
2011). It has been seen that the initial symptoms of the disease are often exertion induced and 
include breathlessness, tiredness, chest pain and syncope, with features of right ventricular 
dysfunction presenting in the advanced stages of the disease (Galie et al., 2015). It has been 
seen that patients with CTEPH present more frequently with oedema and haemoptysis whereas 
patients with IPAH present more frequently with syncope (Lang et al., 2013).  
There may be a failure or relative delay in the diagnosis of this condition as a result of the non-
specific symptoms particularly in patients with no history VTE which might contribute to poor 
long-term outcomes.  
Investigations for CTEPH 
There are a number of different investigations that can be performed in patients with suspected 
CTEPH and these depend on local expertise, availability of infrastructure and personal 
preference. 
Ventilation-perfusion (V/Q) scan is recommended by international guidelines as the first-line 
investigation of choice for suspected CTEPH due to its of ease of interpretation and high 
sensitivity for surgical disease. It has a reported sensitivity and a specificity of 96-97% and 90-
95% respectively for the diagnosis of CTEPH (Tunariu et al., 2007). There are, however, a 
number of limitations to V/Q imaging. Where there is web disease and good distal perfusion, 
V/Q scans might come out normal. It has been seen that the extent of perfusion defects also do 
not correspond well with the disease severity and the readily visible perfusion defects on V/Q 
scan can reduce over time in spite of worsening pulmonary haemodynamics (Moradi et al., 
2019). An awareness of the benefits and limitations of various imaging modalities in the 
assessment of CTEPH is therefore important. 
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Computed tomographic pulmonary angiogram is another recognized imaging technique for the 
diagnosis of CTEPH (He J et al., 2012). High resolution computed tomography of the thorax 
helps visualize the lung parenchyma and may diagnose emphysema, bronchiectasis or 
pulmonary fibrosis. Mosaic attenuation is a common finding in patients with CTEPH but can also 
be seen in patients with IPAH (Sherrick et al., 1997). However, CTEPH might be missed when 
the tomogram is interpreted by individuals not experienced in pulmonary vascular diseases. A 
historical and often quoted manuscript by Tunariu et al. which used older CT techniques 
highlighted that a significant number of patients with CTEPH were missed on CTPA (Tunariu et 
al., 2007). More recent reports with modern techniques have shown excellent sensitivity of 95% 
and specificity of 95% when used in expert hands. This is comparable to V/Q scans (He J et al., 
2012).  
Magnetic resonance pulmonary angiogram exposes the patient to no radiation and is being 
increasingly used in the evaluation of suspected CTEPH as a replacement to CTPA. Rajaram 
and co-workers found a very high specificity and sensitivity profile of Contrast Enhanced MRA in 
diagnosing Chronic Thromboembolism (Rajaram et al., 2012). Another study by the same group 
found that sensitivity and specificity of 3D lung perfusion MRI in diagnosing CTEPH was very 
similar to Q-scan when images are interpreted by radiologists with experience with pulmonary 
vascular disease (Rajaram et al., 2013).  
Right heart catheterisation is also an important diagnostic test that allows for the measurement 
of PVR. In order to identify potential surgical candidates, this measured elevation of PVR is 
compared to the degree of obstruction in the vascular bed which is observed by imaging 
techniques (Dartevelle et al., 2004). Patients with severe elevation of PVR and only modest 
obstruction of the pulmonary vasculature are at a high risk for surgical intervention (due to the 
presence of significant microvascular disease). A combination of drug therapy directed at the 
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pulmonary vasculature and balloon pulmonary angioplasty are the preferred techniques in this 
setting (Delcroix et al., 2021). 
There is an increase in the number of patients with more distal disease profile who are 
undergoing pulmonary endarterectomy and Balloon Pulmonary Angioplasty (BPA) with good 
survival benefit. Hence, there is a greater focus on the assessment of the distal pulmonary 
vasculature. There are several different approaches to assessing the operability and suitability 
for balloon pulmonary angioplasty in CTEPH and the choice depends on the availability of the 
various modalities and the experience of different centres. Historically, studies have shown that 
V/Q scan and CTPA were the most accurate non-invasive investigations for the identification of 
CTEPH with a very high sensitivity and specificity (He J et al., 2012, Lang et al., 2010, Hoeper 
et al., 2005). More recent data has demonstrated the value of MR imaging and increasingly 
centres are using a multimodality imaging approach (Rajaram et al., 2013). Newer imaging 
modalities such as dual energy CT, cone beam CT, and area detector CT provide greater 
resolution of the distal pulmonary vasculature and may be more useful than invasive methods in 
planning surgeries (Kim, 2018b). 
Conventional pulmonary angiography is recommended as the final diagnostic step in the 
workup of patients with CTEPH (Galie et al., 2015, Jenkins et al., 2012). Anterior–posterior and 
lateral views are generally utilised. Although conventional pulmonary angiography is considered 
the gold standard in determining the operability in CTEPH, it is being challenged by recent 
advances in non-invasive imaging techniques. CTPA is increasingly being used in the 
assessment of operability of CTEPH due to its high sensitivity (main/lobar pulmonary arteries: 
89-100% and segmental pulmonary arteries: 84-100%) and specificity (main/lobar pulmonary 
arteries: 95-100% and segmental pulmonary arteries: 92-99%) in detecting thromboembolic 
lesions (Kim, 2018b). In some centres conventional pulmonary angiography is being replaced 
by MRA and CTPA which are non-invasive, cost effective procedures with fewer complications, 
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although, there is limited data on outcomes of patients selected for surgery using these 
approaches. 
More recently the Fleischner society have reviewed the imaging approaches to diagnosing 
CTEPH and have highlighted the importance of a multi-modality approach to guide treatment 
decisions (Remy-Jardin et al., 2021). Whereas historically CTEPH has frequently been missed 
on CTPA, new CT imaging techniques allow for construction of perfusion maps (previously only 
visualised using scintigraphy). These perfusion maps can now be constructed using either dual 
energy CT or lung subtraction iodine maps on single energy scanners and improves the 
detection of CTEPH. Improvements in CT imaging techniques are now also being used to 
identify the proximal extent of thromboembolic disease. This data can be utilised to outline a 
road map for surgery. Conventional pulmonary angiography and digital subtraction angiography 
have previously been considered to be the reference standard for the assessment of CTEPH. 
However, recent advances in surgical techniques are allowing more distal disease to be tackled, 
thus enabling cone beam and ECG-gated CT to provide more precise information on the distal 
pulmonary vasculature and guide treatment. 
Figure 3 shows an algorithm for the diagnostic approach for patients with CTEPH based on the 
2015 European Society of Cardiology guidelines. Figure 4 demonstrates imaging features of 
CTEPH diagnosed using planar perfusion scintigraphy, dynamic contrast enhanced MR 
perfusion imaging, CTPA, and contrast enhanced MR angiography. 
Management of CTEPH 
 
General management of CTEPH 
Standard medical treatment of CTEPH consists of long term anticoagulant therapy and diuretics 
with oxygen therapy in selected patients. Vitamin K antagonists like warfarin have historically 
been the preferred anticoagulant. However, an increasing number of patients are now treated 
with direct oral anticoagulants (DOAC). A report by Mutlu (Mutlu, 2017) involving 97 patients 
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(warfarin group, n=66 vs rivaroxaban group, n=31) suggested that rivaroxaban was as effective 
as warfarin in the prevention of venous thromboembolism in patient with CTEPH with no 
significant difference in bleeding rates. However, retrospective study by Bunclark et al. from the 
UK suggested a higher rate of recurrent VTE in patients treated with DOACs compared to 
warfarin (Bunclark et al., 2020). As of now, more information on DOACs from large scale 
prospective studies are required to measure its clinical effectiveness in patients with CTEPH. 
Including selective management, general preventive measures as for other forms of PH are 
important. These include vaccinations, encouragement of exercise, and counselling regarding 
the risks during pregnancy in women of child-bearing age. The treatment algorithm for chronic 
thromboembolic pulmonary hypertension based on the 2015 European society of cardiology 
guidelines is shown in figure 5. 
PH specific targeted therapy 
Trials have focused on patients with inoperable disease or persistent PH post-PEA. The 
BENEFiT randomised controlled trial showed significant improvement in pulmonary 
haemodynamics in these two patient groups when treated with bosentan after 16 weeks (Jais et 
al., 2008). However, this study did not show any improvement in exercise capacity in the 
bosentan group as compared to the placebo group. In an open labelled uncontrolled study 
Reichenberger et al. found patients with inoperable CTEPH taking sildenafil after 1 year of 
treatment showed significant improvement and maintenance in pulmonary haemodynamics and 
exercise capacity (Reichenberger et al., 2007). Riociguat is a soluble guanylate cyclase 
stimulator that has been licensed in Europe (including UK) for use in patients with inoperable 
CTEPH and persistent PH post PEA surgery. The CHEST 1 & 2 study showed significant 
improvement in exercise capacity and pulmonary haemodynamics in patients with inoperable 
disease or persistent PH post PEA taking riociguat as compared with placebo after 2 years of 
commencement of treatment. Patients receiving riociguat had an improvement in walk distance 
of 39 meters vs 6 meters in placebo group (p<0.001) and a reduction of PVR of 226 
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dyn·sec·cm–5 vs 23 dyn·sec·cm–5 in placebo group (p<0.001) at 16 weeks of follow-up. An 
extension of this study has shown maintenance of the improved exercise capacity for 2 years 
and a 2-year survival rate of 93% (Ghofrani et al., 2013, Simonneau et al., 2016). A multi-
centre, randomised, double blind, placebo-controlled trial by Ghofrani and co-workers involving 
80 patients with inoperable CTEPH (MERIT-1) demonstrated a decrease in PVR after 16 weeks 
of treatment with Mactentan, an endothelin receptor antagonist (ERA) as compared to placebo. 
They reported that PVR decreased to 73% of baseline in the macetentan group (n=34) vs 87% 
of baseline in the placebo group (n=40). The trial also showed improvement of 6-minute walk 
distance after 24 weeks of follow-up (35m in macitentan group vs 1 m in placebo group). 
Macitentan was well tolerated with only 23% of patients having peripheral oedema and 15% of 
patients having decreased haemoglobin (Ghofrani et al., 2017). Data from the OPUS 
(OPsumitUSers) registry by Kim and co-workers involving 40 patients with inoperable CTEPH 
on macitentan with median follow-up period of 15 months also showed a good safety profile. In 
this study only 5% patients had peripheral oedema and 2.5% patients developed anaemia (Kim, 
2018b, Kim, 2018a). 
PH specific targeted therapy are beneficial in patients with distal disease and persistent PH post 
PEA. However, to date very limited data exist on the clinical course of patients who have 
operable disease who do not undergo surgery and are on pulmonary vasodilator therapy. Table 
3 shows the RCTs with PH specific targeted therapy in patients with distal disease and 
persistent PH post PEA. 
Pulmonary endarterectomy (PEA) 
Pulmonary endarterctomy (PEA) is the treatment of choice in patients with proximal CTEPH. It 
offers the most benefits with respect to improved quality and quantity of life (Bonderman et al., 
2007) (Galie et al., 2015) (Konstantinides, 2014). The routine use of PEA in CTEPH is based on 
retrospective observational data from San Diego, USA where the 10 year survival following PEA 
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surgery was found to be 75% (Jamieson SW, 2003). This was a dramatic improvement as 
compared to historical cohorts where the 5 year survival was < 20% (Riedel M, 1982). Suitability 
for PEA surgery is generally determined by various factors which include the location of the 
occlusion and pulmonary haemodynamic measurements. Surgically accessible pulmonary 
vascular occlusions are proximal lesions and include the main, lobar and segmental arteries 
(Jenkins et al., 2017). The number of surgically accessible pulmonary vascular occlusions on 
multimodality imaging and imbalance between the pulmonary vascular resistance at right heart 
catheterization are important criteria in determining operability (Delcroix et al., 2021). In addition 
to these, advanced age, multiple co-morbidities, and poor general health condition are taken 
into consideration while assessing operability. There are no strict criteria for operability and 
patient selection and depends on the experience of the unit performing the procedure (Jenkins 
et al., 2017) although an expert PEA centre can perform more distal segmental pulmonary 
endarterectomies with less complications and excellent survival (Kim, 2018b) compared to less 
experienced centres (Kim, 2018b).  
PEA is a potentially curative procedure (Kim et al., 2013). However, it is a major undertaking 
which requires a median sternotomy to be performed under total circulatory arrest with the 
patient on cardiopulmonary bypass under profound hypothermia (cooling to 20o Celsius) 
(Jenkins et al., 2017). In terms of surgery, the usual approach is to perform an incision in the 
right main pulmonary artery and extend it to the right lower lobe. From there the organized 
thromboembolic material is dissected up to the subsegmental level (Jamieson SW, 2003). The 
residual layer after dissection of the organized clot is usually a pearly white smooth vessel wall 
(Jenkins et al., 2017). Circulatory arrest is restricted to 20-minute intervals while right-sided 
pulmonary endarterectomy is being performed and the procedure is usually completed within 
this time. Once the right sided endarterectomy is completed, the cardiopulmonary bypass is 
restarted, and patient is re-perfused while the incision of the right side is being closed. This 
procedure is repeated in the left side under similar conditions (Jamieson SW, 2003). The luminal 
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diameter of the PEA surgical specimens range between 5mm and 40mm (Southwood et al., 
2016). The patients usually remain in hospital for 10-14 days following surgery (Taboada et al., 
2014). The international prospective CTEPH registry suggested that the in-hospital mortality for 
patients undergoing PEA was relatively low, at around 4.7% (Pepke-Zaba et al., 2011). Cannon 
and co-workers reported an in-hospital mortality post PEA of 2-3% in a more recent cohort from 
the UK (Cannon et al., 2016). These provide increasing evidence that high volume PEA centres 
(performing > 50 cases per year) have significantly low postoperative mortality rates. Despite 
this, Pepke-Zaba et al. found that a significant proportion of patients with CTEPH were 
considered inoperable (Pepke-Zaba et al., 2011). Furthermore, a proportion of patients falling in 
the operable group did not undergo surgery.  
Data from the various studies have shown excellent long-term survival in patients with operable 
disease following PEA very similar to those originally reported by Jamieson and colleagues in 
San Diego. Furthermore, the postoperative mortality has significantly reduced in the recent 
years. This may be attributed to the better selection of patients, refined surgical techniques, and 
advanced postoperative care.  
Balloon pulmonary angioplasty 
Balloon pulmonary angioplasty (BPA) is a treatment option in patients with inoperable CTEPH 
due to distal disease distribution or persistent PH post PEA surgery. BPA is a percutaneous 
interventional procedure performed by cardiologists who are specially trained in this procedure. 
It involves treating the pulmonary vascular occlusions with balloons at comparatively low 
pressures over a number of sessions. Each session is usually restricted to one lobe. This 
procedure is performed in selected centres in Europe where there is expertise but has been 
pioneered in Japan (Wilkens et al., 2018). This procedure has routinely been made available in 
the UK since April 2018. The Royal Papworth Hospital is the UKs first nationally designated 
centre for BPA (2018).  
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Feinstein and co-workers found improvements in pulmonary haemodynamics and clinical status 
in patients with inoperable CTEPH who had undergone BPA, albeit with higher complication 
rates of reperfusion pulmonary oedema and mechanical ventilation (Feinstein et al., 2001). 
Mizoguchi et al. reported similarly improved pulmonary haemodynamics and clinical status with 
lower complication and mortality rates in patients with inoperable CTEPH who underwent a 
refined technique of BPA (Mizoguchi et al., 2012). A report by Inami and co-workers involving 
176 patients with CTEPH who underwent BPA (with a median follow-up period of 2.8 years) 
showed excellent long-term survival (five year survival of 95.5%) and maintenance of pulmonary 
haemodynamics (mPAP and PVR) over 3.5 years follow-up period (Inami et al., 2016). BPA has 
evolved as an acceptable and routinely practiced alternative in patients with CTEPH who are 
unable to undergo PEA surgery for various reasons including distal disease distribution and 
comorbidities, with excellent long-term survival, maintenance of pulmonary haemodynamics, 
reduced postoperative complications and improved exercise capacity. Increasingly BPA is also 
being considered as an adjunct to both medical and surgical therapy. 
However, the role of BPA in patients with technically operable CTEPH who are unable to 
undergo PEA is still not clear (Kim, 2018b) (Galie et al., 2015). Research has recognised that 
there may be an overlay where patients may be suitable for either BPA or surgery. Increasingly, 
treatment approaches to CTEPH are including a multimodal approach where some patients 
may have surgery, BPA, and drug therapy  (Delcroix et al., 2021).  
Lung transplantation 
Finally, lung transplantation may be an option in selected group of patients with CTEPH 
(absence of significant comorbidities and age below 60 years) who are deteriorating despite 
optimal treatment (Wilkens et al., 2018). There are a very limited number of donors for lung 
transplantation in the UK. Analysis of data from the UK national PH audit for 2018 found that 
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only three patients have undergone lung transplantation in that year (Gibbs, 2018). For this 
reason, the waiting list for lung transplantation in the UK is over a year.  
Summary of Research focus 
Aim of the study 
The aim of the study was to describe the baseline characteristics, compare the long term 
survival and identify prognostic indicators in patients with CTEPH undergoing pulmonary 
endarterectomy (CTEPH-surgical-operated), technically operable disease not undergoing 
surgery (CTEPH-surgical-not-operated) and its sub-groups (declining surgery due to patient 
choice, lack of fitness for surgery and other contributors to symptoms in addition to clot burden)  
and technically in-operable disease (CTEPH-non-surgical-disease distribution). Patients with 
technically operable disease who have not undergone surgery and its sub-groups will be the 
primary focus of the study. Furthermore, this study aims to identify the rationale for treatment 
decisions in patients with technically operable disease who have not undergone surgery. It is 
anticipated that work from this thesis will help provide more up-to-date data on the long-term 
survival of patients with technically operable disease who have not undergone surgery and 
identify prognostic factors which may be helpful when counselling patients. 
Conclusion  
The field of CTEPH has evolved rapidly over the past two decades. However, despite much 
progress it still remains a debilitating condition for many. In addition, there remain unanswered 
questions regarding the long-term survival of patients with technically operable disease who 
have not undergone surgery. The work from this study will help provide more up-to-date 
prognostic data on the long-term survival of patients with technically operable disease who have 






Table 1:  Classification of pulmonary hypertension (Galie et al., 2015)  
 
Group Nomenclature 
1 Pulmonary arterial hypertension 
2 Pulmonary hypertension due to left heart disease 
3 Pulmonary Hypertension due to lung disease and /or hypoxia 
4 Chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions 



















Table 2: Surgical classification of CTEPH ((Madani, 2016). 
 
Disease type Distribution of clot 
0 No evidence of clot 
I At the level of the main pulmonary arteries 
II At the level of the lobar and intermediate pulmonary arteries 
III At the level of segmental arteries only 
















































































































































































1 BENEFIT Bosentan ERA 16 157 II-IV 342 (84) +2 (NS) 
778(32
3) -24 
(Jais et al., 
2008) 











Definition of abbreviations; SN = serial number; RCT = randomised controlled trial; CTEPH = chronic thromboembolic pulmonary hypertension; 
ERA = endothelin receptor antagonist; sGCs = soluble guanylate cyclase stimulator; NYHA = New York Heart Association Functional Class; 


















Figure 1: Pathophysiology of CTEPH (Lang et al., 2016) 
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Figure 2: Risk factors for CTEPH 
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*Family history of VTE 
 *Thrombophillic disorders: 
 
Factor V Leiden deficiency 
Prothrombin gene mutation 
Protein C deficiency 
Protein S deficiency 
Anti-phospholipid syndrome 
Anti-thrombin 3 deficiency 
 Associated medical conditions: 
+Splenectomy 
+Other major surgery 
VA shunt 

















* More common in patients with operable disease 
+ More common in patients with in-operable disease 
Definition of abbreviations; CTEPH = chronic thromboembolic pulmonary hypertension; VTE = venous thromboembolism; APE = acute 
pulmonary embolism; VA = ventriculo-atrial; CCF = congestive cardiac failure; CAD = coronary artery disease; MI = myocardial infarction; OCP 









Figure 3: Algorithm for diagnostic approach for patients with CTEPH(Galie et al., 2015) 
 
 Clinical features suggestive of CTEPH  
   
 Echocardiogram suggestive of possible PH  
   
 V/Q scan showing mismatched perfusion defects  





Refer to National PH centre Investigate for other forms of PH/PAH 
  
CTPA, RHC, MRA ± DSA  
 
 
Definition of abbreviations; CTEPH = chronic thromboembolic pulmonary hypertension; PH = pulmonary hypertension; V/Q = ventilation – 
perfusion; PAH = pulmonary arterial hypertension; CTPA = computed tomography pulmonary angiogram; RHC = right heart catherisation; MRA 














Figure 4: Non-invasive multimodality imaging in chronic thromboembolic disease. 
 
 
Non-invasive multimodality imaging in chronic thromboembolic disease. Bilateral segmental perfusion defects (white arrows) demonstrated on 
(A) planar perfusion scintigraphy, (B) 3D dynamic contrast enhanced perfusion MRI and (C and D) CTPA with the typical findings of a central 
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Definition of abbreviations; CTEPH = chronic thromboembolic pulmonary hypertension; PH = pulmonary hypertension; PEA = pulmonary 










































A patient registry can be defined as “an organized system that uses observational study 
methods to collect uniform data (clinical and other) and to evaluate specified outcomes for a 
population defined by a particular disease, condition or exposure and that serves one or more 
predetermined scientific, clinical, or policy purposes” (Gliklich and Campion, 2010). The purpose 
of a patient registry is to describe the clinical course of the disease, evaluate clinical or cost 
effectiveness in the day-to-day practice of medicine, assess risk, and determine the quality of 
care. The major advantage of a patient registry is that it is generally inexpensive. Also, being 
consecutive in nature it might reduce selection bias. Disadvantages of a patient registry include 
the quality of the information collected that may be variable or inaccurate, an inability to 
accurately compare outcomes between groups, and a difficulty in adjusting for confounding 
factors, despite the availability of modern statistical methods (Gliklich and Campion, 2010). 
Table 4 highlights important registries in patients with CTEPH. 
Previous and current registries with a focus on CTEPH 
Registries have shown poor long-term survival in CTEPH if left untreated or on anti-coagulation 
alone. These included patients with mild forms of the condition, patient with distal disease, and 
patients with technically operable disease not undergoing surgery (Riedel M, 1982, Lewczuk et 
al., 2001). The first PEA surgery was performed by Moser and Braunwald in UC San Diego in 
the 1971 and since then the San Diego group have performed over 3000 PEAs. From the UC 
San Diego registry data it can be identified that the prognosis of patients have improved 
remarkably with PEA with the most recent data suggesting a postoperative mortality of only 
around 1% (Jamieson SW, 2003, Madani et al., 2012). The UK national PEA programme based 
at the Royal Papworth Hospital have performed over 2000 PEAs since 1996 with a 
postoperative mortality of around 2.2%. Using their registry data, Cannon and co-workers 
looked primarily at the long-term survival and prognostic indicators in patients undergoing PEA 
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(Cannon et al., 2016). In a UK wide registry Condliffe et al. compared the long-term survival and 
prognostic indicators in patients with CTEPH who underwent PEA surgery with patients who 
were considered inoperable due to distal disease distribution and reported similar findings 
(Condliffe et al., 2008, Condliffe et al., 2009). Similar findings were also obtained by the analysis 
of the International CTEPH registry data by Delcroix & Pepke-Zaba and co-workers involving 
European countries as well as North America (Canada) (Pepke-Zaba et al., 2011, Delcroix et al., 
2016). Delcroix et al. also assessed the survival and prognostic indicators in patients with 
CTEPH not undergoing PEA surgery or BPA as compared to patients with persistent PH post 
PEA surgery receiving PH-specific targeted therapy (Delcroix et al., 2018). Similar studies with 
similar results have also been reported by smaller registries in Europe (Escribano-Subias et al., 
2016). Registry data of patients with inoperable CTEPH undergoing BPA have also shown 
excellent survival (Inami et al., 2016).  
The UK National audit is hosted by NHS digital and commissioned by NHS England. Data is 
collected prospectively by all adult centers and the national children’s center for PH at Great 
Ormond Street. There are over 30,000 patients with all forms of pulmonary hypertension 
including over 3000 patients with CTEPH enrolled in the national audit since 2009. This audit 
also confirms the excellent long-term survival following surgery with low surgical mortality rates 
(Kiely DG, 2021). 
Interestingly, a thorough search of the existing literature did not find any research that 
specifically looked at the long-term survival and prognostic indicators in patients with technically 
operable CTEPH not undergoing surgery and its sub-groups (patient choice of declining 
surgery, being unfit for surgery and patients with mild disease). Furthermore, there are no 
comparisons of the long-term survival of patients with CTEPH who underwent surgery versus 





Patient pathway in the management of CTEPH in the UK 
In the UK there are eight nationally designated Pulmonary Hypertension (PH) centres across 
five cities. They include London (Great Ormond Street Hospital for children, Royal Free 
Hospital, Hammersmith Hospital and Royal Brompton Hospital), Glasgow (Golden Jubilee 
Hospital), Newcastle (Freeman Hospital), Cambridge (Royal Papworth Hospital), and Sheffield 
(Royal Hallamshire Hospital). Each centre acts as a referral centre for a specific geographical 
area in the UK and has a team of experts (physicians, radiologists, specialist nurses) qualified 
to investigate and treat patients with PAH and CTEPH (Gibbs, 2018). Importantly, each centre 
needs to adhere to national standards of care and results are published annually in the UK audit 
(Kiely DG, 2021) 
The Sheffield Pulmonary Vascular Disease Unit (SPVDU) is the largest nationally designated 
PH centre in the UK, having over 2,000 active patients with PH (including PAH and CTEPH) 
(Gibbs, 2018). In Sheffield patients are referred from the Midlands, North West, Yorkshire and 
Humber, and Wales, covering a referral population of approximately fifteen to twenty million. 
The Royal Papworth Hospital, Cambridge is the UK’s national PEA centre, receiving referrals of 
patients with CTEPH (for PEA and BPA) from all of UK’s PH centres. It has performed over 
2000 PEAs since 1996 (Papworth Hospital) with 166 PEAs performed between 2017 and 2018 
reporting excellent long-term survival (Cannon et al., 2016, Gibbs, 2018) . The pathway for the 
management of CTEPH at the SPVDU is outlined in figure 6 and the follow-up management 
post-PEA at the national centre is outlined in table 5. 
Establishing a database for collection of CTEPH data 
Background 
Data for the current study was initially intended to be collected into the ArQ PH research 
database. This is a data collection software created by the medical informatics and medical 
physics team at the Royal Hallamshire Hospital on behalf of the University of Sheffield, School 
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of Medicine and Sheffield Teaching Hospitals NHS Foundation Trust for research into patients 
with all forms of pulmonary hypertension (PH). I worked with my colleagues at the University of 
Sheffield and the local software developers to create new fields within the existing ArQ PH 
research database to meet the requirements for the proposed study. After having worked for 6 
months with this project it was realized that within the available time frame it could not 
guaranteed that this database would be complete to allow for the completion of this study. The 
previous ASPIRE 1 registry was then considered to input the data. The ASPIRE registry 1 was 
a departmental database using Microsoft Access and was created to collect data for patients 
with all forms of PH. However, the ASPIRE 1 registry was found to not be suitable for the study 
as it did not have all the required fields and consequently I opted to develop a specific database 
for the purpose of this study. 
Creation of a new database: ASPIRE 2 registry 
After doing extensive research into the development of data collection software I opted to create 
a new database with the help of external software developers. The data collection software was 
required to be simple to use, secure, specific, valid, reliable, cost effective, with IT backup 
support and in accordance with the Trust’s information governance policy. I chose Renvir to 
design the ASPIRE CTEPH registry database. Renvir is a subsidiary of Electronic Business 
Solution Limited. The software was initially created as a web-based interface which could store 
the data. Later due to potential concerns regarding the safety of data it was converted into a 
desktop application. The database was developed using Windows Form application (C#.NET) 
and Microsoft SQL Server 2008 (Express Edition). System requirements to run the applications 
included a minimum operating system (OS) of Windows 7 and a random-access memory (RAM) 
of 2 GB. I carried out pilot data collection and made further changes and alterations to the 
software during the developmental and troubleshooting stages of the project. Following an initial 
pilot of data entry from 10 patients I employed a significant update to the software with 
subsequent smaller modifications and refinements before it was ready to be used for this study. 
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The entire development process took 12 months. 
The developmental process of the ASPIRE 2 registry database included a number of meetings 
with my academic supervisor to agree upon the variables to be captured in the new database 
based on previous literature and expert opinion. The detailed sequence of events has been 
summarised in the following steps. 
a) Extensive search of the CTEPH literature and previous registries was done to identify 
key variables to be collected and identification of additional variables relevant to the 
specific area of study. 
b) Use of an Excel format to display variables and time points was decided upon. 
c) Several meetings were conducted with Trust and University IT department to ensure that 
clinical governance processes were followed with safety of data and data confidentiality, 
which were key components of the study. Subsequent discussion within the Trust to 
develop an in-house bespoke system to allow for ease of data collection and simple 
extraction of data to Excel to allow for analysis using standard statistical packages was 
done. Due to cost and time pressures it was established that the Trust would be unable 
to support development of this database. 
d) Extensive research was performed to identify an external software developer in the UK 
and abroad. An external software developer in Bangladesh was identified that was able 
to deliver the planned configuration of the database. A contract with the software 
developers regarding creation of data collection software and provision of backup IT 
support and maintenance for one year was established at a cost of 1200 GBP. It was 
specified that the database should be user friendly and could be used for future 
prospective and retrospective data collection in patients with CTEPH. 
e) Permissions were obtained from Sheffield University Hospitals NHS FT IT department to 
install software applications on Trust computers.  
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f) Multiple remote meetings with software developers were conducted regarding the 
development of the bespoke database. 
g) With the help of TEAMVIEWER I was able to facilitate the software developers to 
remotely enter a Trust laptop and install the programme and provide the initial login ID 
and password (which was later changed). 
h) Initial pilot data entry of 10 patients was done. The data was exported it to Excel format 
where I found multiple problems, including certain data which were entered into the 
database but did not appear in the spreadsheet after exporting. 
i) Multiple further changes were identified to be made for the improvement of the database 
configuration and usability.  
j) Further discussions were conducted with the software developer through TEAMVIEWER 
and telephone regarding the problems faced and corrections. 
k) Discussions done with Trust IT department on whether certain data such as bloods tests, 
pulmonary function tests, right heart catheter studies and cardiac MRI results could be 
directly imported to the database. It was informed by IT department that this was not 
possible at that time. I discussed it with my academic supervisor who agreed to input 
these data manually. 
l) Initially software was web based but due to potential data protection issues academic 
supervisor suggested making it computer based which was implemented. 
m) Had a further pilot data of 40 patients entered into the database and reviewed the 
exporting of the data to Excel format. More issues were identified including 
disappearance of certain variables in the spreadsheet which were present in the input 
section. Requested further changes of the software from the developers. 
n) After the issues were sorted out, a final discussion was conducted with the developer 
team and the academic supervisor. The academic supervisor was satisfied with the 
working of the software and agreed to the starting of the data collection procedure. 
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Figure S1-S12 show the snapshots of the ASPIRE 2 registry database and table S1 shows the 
differences between ASPIRE 1 and ASPIRE 2 registry databases. 
Methods 
Consecutive treatment naïve patients with newly diagnosed CTEPH at the Sheffield Pulmonary 
Vascular Disease Unit between 1st January 2001 and 30th November 2014 were identified and 
followed up until the 30th of November 2015. 
Data pertaining to baseline characteristics, treatment and follow-up of the patients were 
collected from hospital records and departmental databases. Baseline characteristics included 
demographics, presenting symptoms, past medical history and investigations including blood 
testing, pulmonary function, exercise testing, right heart catheter studies, and imaging which 
included isotope perfusion scanning, computer tomography pulmonary angiography, magnetic 
resonance angiography, cardiac magnetic resonance imaging and digital subtraction 
angiography (DSA). Data on PH specific targeted therapy, PEA surgery and anticoagulation 
were also collected. Follow-up data included World Health Organization functional class, 
incremental shuttle walk distance, pulmonary function test, right heart catheter studies and 
cardiac magnetic resonance imaging.  
The diagnosis of CTEPH was based on findings obtained after at least 3 months of anti-
coagulation and required a mean pulmonary arterial pressure ≥25 mm Hg at rest and at least 
one segmental perfusion defect detected by perfusion lung scan or pulmonary artery obstruction 
seen by MDCT angiography or conventional pulmonary angiography with other causes of PH 
excluded (Galie et al., 2015). Patients were further classified into a) surgical-operated group, 
consisting of patients with surgically accessible disease who underwent PEA surgery, b) 
surgical-not-operated group, consisting of patients with surgically accessible disease who did 
not undergo PEA surgery and c) non–surgical group, consisting of patients with inoperable 







classified into five categories based on the reasons for the surgery not being performed. These 
included patients’ choice, being unfit for surgery (due to age and co-morbidities), awaiting 
surgery at the time of census, chronic thromboembolic disease (CTED) with co-morbidities 
where symptoms may be related to other factors in addition to CTED, and reason for decision 
not clear. Patients awaiting surgery at the time of census were excluded from the analyses. 
Suitability for PEA surgery was assessed by a review of clinical and radiological information by 
the surgical multidisciplinary team at Papworth Hospital, Cambridge. This team included 
pulmonary vascular radiologists, physicians and nurses together with PEA surgeons. Data 
regarding clinical status, standard investigations including RHC and the appearance of at least 
two radiological investigations were considered when deciding operability. Patients who were 
deemed to have potentially operable disease were invited to meet the surgical team at 
Papworth. Only after a face-to-face surgical review were patients asked to make a decision 
regarding surgery. 
The date at which the patient was first diagnosed as having CTEPH was recorded as the date 
of the first right heart catheterization. All the patients were followed up until death or the census 
end date of 30th November 2015. Mortality data was obtained from the hospital records at this 
date. Ethical approval was granted for this study (REC Reference number 06/Q2308/8). This 
study was registered in ClinicalTrials.gov (ID: NCT02565030, dated 28/09/2015). 
Statistical analysis 
Descriptive data was presented using mean and standard deviation (SD). Comparison between 
groups was made using t-test and ANOVA (with Bonferroni corrections for three groups) for 
continuous data and Chi-squared tests for categorical data. Survival was assessed by the 
Kaplan-Meier analysis method. Further comparisons between two groups were performed using 
log-rank test. A total of 74 variables in CTEPH-whole cohort, 72 variables in CTEPH-surgical-
operated, 71 variables each in CTEPH-surgical-not-operated and CTEPH-non-surgical disease 
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distribution group were identified based on previous literature and expert opinion (table S2) 
(Delcroix et al., 2016) (Condliffe et al., 2008). Prognostic variables were assessed using 
univariate and multivariate cox regression analysis for survival. After univariate cox regression 
analysis variables with a p value of < 0.20 with missing data of < 10% were included for the 
multivariate analysis using forward logistic regression method. A p value of < 0.05 was 
considered statistically significant. Accuracy of variables was assessed by using receiver 
operator characteristic (ROC) analysis and area under the curve (AUC). Furthermore, 
sensitivity, specificity, NPV, and PPV were calculated. The statistical analysis was performed 
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Austria Prospective 1992-2013 PEA 214 91%    
Risk factor for 30-day 
mortality- high PVR, 
NYHA FC IV, and low CI. 
Risk factor for mortality in 
first 6 months after PEA-
high PVR, Reduced CI 
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France Retrospective 2005-2009 
CTEPH-
operated 383 93% 92%   Age and PVR (Tromeur et al., 2018) 
 
Definition of abbreviations; CTEPH = chronic thromboembolic pulmonary hypertension; mPAP = mean pulmonary artery pressure; COPD = chronic obstructive pulmonary disease; PEA = pulmonary endarterectomy; 
PVR = pulmonary vascular resistance; IPAH = idiopathic pulmonary arterial hypertension; WHO FC = World Health Organisation functional class; PaO2 = partial pressure of oxygen(arterial);  6MWD = 6 minute walk 
distance; NYHA = New York heart association; RAP = right atrial pressure; H/O = history of; PH = pulmonary hypertension; CAD = coronary artery disease; LVF = left ventricular failure; CI = cardiac index; BPA = 
balloon pulmonary angioplasty; Kco = carbon monoxide transfer co-efficient; BNP = brain natriuretic peptide;   
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Table 5: Follow-up at the national PEA centre following pulmonary endarterectomy 
(Ponnaberanam A., 2015, Taboada et al., 2014) 
 
Time following surgery Location Follow-up Investigations 
3-6 months Papworth Hospital, Cambridge 
CAMPHOR QoL, WHO FC, 
Blood tests, ECG, Chest 
radiograph, Echo, PFT, 6MWT, 
RHC, CTPA and or MRI 
12 months Papworth Hospital, Cambridge or local PH centre 
As day case or in-patient based 
on the investigations required 
(usually all the above and RHC in 
patients with elevated PAP at 
initial 3-6-month post-op RHC) 
 
Definition of abbreviations; QoL = quality of life; WHO FC = World Health Organization functional class; PTE = pulmonary 
thromboendarterectomy; ECG = electrocardiogram; PFT = pulmonary function test; 6MWT = six-minute walk test; RHC = right heart 


















Figure 6: Patient pathway in the management of CTEPH at the SPVDU 
 
 
            
            
            
             
 
      
            
            
  
            
        
  
            
             
            
 
            
 
             











Definitions of abbreviations; PH = pulmonary hypertension; CTEPH = chronic thromboembolic pulmonary hypertension; CTPA = computed 
tomography pulmonary angiogram; Q Scan = perfusion scan; CMR = cardiac MR; MRA = magnetic resonance angiography; RHC = right heart 
catheterization; QoL = quality of life; National PEA MDT consists of pulmonary vascular physicians, interventional cardiologists, radiologists, 







Patient referred with suspected PH and or CTEPH 
 
Visit 1: ECG, Bloods, Exercise & Lung Function Test, Echo & clinical review 
Visit 2: Patient admitted as a day case for investigations (CTPA, Q Scan, 
CMR +MRA, RHC) & QoL questionnaire 
If CTEPH diagnosed, option for treatment discussed and patient referred to 
Papworth MDT 
 
Discussion at MDT, Papworth confirming operability assessment  
 
PEA performed at Papworth 
 
Patient on waiting list for surgery 
 
All technically operable patients with acceptable risk benefit ratio invited 
by PEA surgeons for a face to face meeting at Papworth 
 
Follow-up by the Papworth PEA team/ and to SPVDU for the first 12 
months post-surgery including routine RHC studies at 3 months following 
surgery 
 
Follow-up for up to five years by the national PH centre and discharged if 
remains well 
 
Patient with residual PH followed up at SPVDU 
Candidates not offered surgery 












Chapter 3: Long term outcome, prognostic and 
aetiological factors and the impact of patient 
choice on survival in chronic thromboembolic 
pulmonary hypertension 











Pulmonary endarterectomy (PEA) is the gold standard treatment for operable chronic 
thromboembolic pulmonary hypertension (CTEPH). However, a proportion of patients with 
operable disease decline surgery. There are currently no published data on this patient group. 
The aim of this study was to identify outcomes and prognostic factors in a large cohort of 
consecutive patients with CTEPH. 
Methods 
Data was collected for consecutive, treatment-naïve CTEPH patients between 2001-2014 
identified from the ASPIRE registry.  
Results 
Of 550 CTEPH patients (age 63±15 years, follow-up 4±3 years), 49% underwent surgery, 32% 
had technically operable disease and did not undergo surgery (including patient choice n=72, 
unfit for surgery n=63) and 19% had inoperable disease due to disease distribution. Five-year-
survival was superior in patients undergoing PEA (83%) versus technically operable disease 
who did not undergo surgery (53%) and inoperable due to disease distribution (59%), p<0.001. 
Survival was superior in patients following PEA compared to those offered but declining 
surgery (55%), p<0.001. In patients offered PEA, independent prognostic factors included 
mixed venous oxygen saturation, gas transfer and patient decision to proceed to surgery. 
Conclusions 
Outcomes in CTEPH following PEA are excellent and superior to patients declining surgery 
and strongly favour consideration of a surgical intervention in eligible patients.  




Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a potentially curable form of 
pulmonary hypertension (PH) (Kim et al., 2013). It may follow an acute episode of pulmonary 
embolism (PE) (Lang et al., 2013) (Pepke-Zaba et al., 2013b) but can present as unexplained 
PH with no previous history of venous thromboembolism (VTE) (Hoeper et al., 2006, Humbert 
M, 2010,  Lang, 2004). CTEPH occurs as a consequence of failure of clot resolution and 
secondary pulmonary arterial vasculopathy leading to the development of PH, right ventricular 
dysfunction and ultimately death (Humbert M, 2010, Moser and Braunwald, 1973). Over the 
past 20 years the treatment of CTEPH has evolved to include pulmonary endarterectomy 
(PEA) in operable cases (Jamieson SW, 2003) and PH specific therapy for inoperable disease 
(Cannon JE, 2013, Ghofrani et al., 2013, Ghofrani et al., 2017, Jais et al., 2008, 
Reichenberger et al., 2007, Simonneau et al., 2016, Suntharalingam et al., 2008). Balloon 
pulmonary angioplasty is emerging as a potential treatment option in selected patients with 
inoperable disease (2018) (Kim et al., 2013, Feinstein et al., 2001,  Galie et al., 2015, 
Mizoguchi et al., 2012, Inami et al., 2016). 
Pulmonary endarterectomy is currently considered the treatment of choice in patients with 
operable CTEPH and is associated with excellent symptomatic benefit and long-term survival 
(Bonderman et al., 2007, Galie et al., 2015, Konstantinides, 2014) with 10-year survival of 72-
75% (Cannon et al., 2016, Madani et al., 2012). Historical studies in patients treated with 
anticoagulation alone reported a 5-year survival of as low as 10% in patients with a mPAP of > 
50mmHg (Lewczuk et al., 2001, Riedel M, 1982). However, subsequent large registries have 
shown significant improvements in outcome in a heterogeneous group of non-operated 
patients (Delcroix et al., 2016, Escribano-Subias et al., 2016). Patients with CTEPH may be 
deemed inoperable where the pulmonary vascular resistance is deemed to be out of 
proportion to the degree of surgically accessible obstruction in the pulmonary vasculature 
(Delcroix et al., 2016, Pepke-Zaba et al., 2011). A significant proportion of patients who have 
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technically operable disease do not undergo surgery for a variety of reasons including 
comorbidities and patient choice (Delcroix et al., 2016, Escribano-Subias et al., 2016, Pepke-
Zaba et al., 2011, Hurdman et al., 2012, Bunclark, 2017, Gall et al., 2017). To date, there are 
only limited data on the clinical course and rationale for treatment decisions in this patient 
group. In particular, there is very limited data on patients with technically operable disease who 
have declined surgery. 
The aim of the current study was to provide data to help inform patient choice by identifying 
outcomes and prognostic factors in a large cohort of consecutive patients with CTEPH.  
Methods 
The methods are described previously in chapter 2. 
Statistical Analysis 
The statistical analyses are described previously in chapter 2. 
Results 
Five hundred and fifty patients with CTEPH (mean age 63±15 years, 50% female) were 
identified.  A flow chart showing the classification with detailed breakdown of patients is shown 
in figure 7. The number of patients newly diagnosed with CTEPH at the study centre each year 
between 2001 and 2014 is shown in figure 8. 
Patient characteristics 
CTEPH (whole cohort) 
Baseline characteristics for the major groups are summarised in table 6. There was excellent 
data completeness with data on lung function testing, exercise testing and imaging available in 
94%, 94% and 93% of patients respectively. Right heart catheterisation was performed in all 
patients. Survival data up to the census end date was available for all patients. The most 
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common presenting symptoms were breathlessness (98%), ankle swelling (38%), pre-syncope 
(27%) and chest pain (19%). There was no significant difference in symptoms or duration of 
symptoms prior to diagnosis between patients with a non-surgical disease distribution and 
those with technically operable disease (both undergoing not undergoing surgery). Ninety-five 
percent of patients were white with no significant difference in ethnicity between the CTEPH 
groups. With respect to anticoagulation, 90% of the patients received a vitamin K antagonist, 
4.5% received anti-Xa oral anticoagulants and 5% low molecular weight heparin while 0.5% 
did not receive any anticoagulation therapy. Seventy-six percent of patients received PH 
specific therapy, of whom 315 received PDE-5i monotherapy, 49 endothelin receptor 
antagonist monotherapy, 22 prostanoid monotherapy, 18 combination therapy with a PDE-5i 
and endothelin receptor antagonist and 12 combination therapy with a PDE-5i and prostanoid. 
No patients received riociguat (table 7). 
CTEPH - operated  
Patients with CTEPH who underwent surgery were younger with a male predominance, better 
exercise capacity, and gas transfer as compared to patients in the other groups (table 6). The 
mean waiting time from date of diagnosis to surgery at the UK PEA centre was 290±175 days. 
Seventy-four percent received bridging therapy, of whom 74% received monotherapy with 
phosphodiesterase-5-inhibitors. Bridging therapy commenced at diagnosis and therefore did 
not lead to delay in referral for surgical consideration or time to surgery (table 8). 
CTEPH - declined surgery (patient choice) 
Compared with patients undergoing PEA, patients who declined surgery were older, more 




CTEPH – technically operable not offered surgery (unfit for surgery, other contributors to 
symptoms in addition to clot burden)  
Patients who were unfit for surgery had worse exercise capacity, lower DLCO, were more likely 
to be current smokers and had a higher prevalence of COPD than other technically operable 
patients not undergoing surgery. Patients with other contributors to symptoms in addition to 
clot burden (where the risk of surgery was felt to outweigh the benefit) had milder pulmonary 
haemodynamics and a better exercise capacity than the other 2 sub-groups. The baseline 
characteristics of these patients are described in further detail in table 10. 
CTEP - non-surgical disease distribution 
History of VTE was less common in patients with non-surgical disease. However, history of 
thyroid disease and splenectomy was significantly more common in this sub-group compared 
to patients undergoing PEA (table 6). 
Outcomes 
CTEPH (whole cohort) 
During a mean follow-up of 4±3 years, 182 (32%) patients died: 51 in the CTEPH surgically 
operated group, 76 in the CTEPH technically operable but not operated group and 49 in the 
CTEPH non-surgical group. Estimated 1, 3 and 5-year survival from date of right heart 
catheterisation was superior in the CTEPH operated group (97%, 87% and 83%) compared to 
both the CTEPH technically operable but not operated group (87%, 63% and 53%) and 
CTEPH non-surgical group (92%, 75% and 59%); p<0.001, (figure 9).  
CTEPH - operated  
Persistent PH (as defined by mPAP ≥ 25 mmHg) post-PEA surgery was found in 108 (40%) 
patients in this study. There was no significant difference in long term survival between the 
patients who developed PH post-PEA versus the patients who did not develop PH post-PEA 
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(p=0.288, figure 10). However, those with a post-operative PVR above the median (3 WU) had 
a worse prognosis following surgery (p=0.013, figure 11). There was no significant difference 
in survival between patients who received bridging therapy versus patients who did not receive 
bridging therapy prior to surgery (3-year survival 86% versus 90%, p=0.447, figure 12) as per 
univariate analysis (HR 0.772, CI 0.39-1.51, p = 0.448), although those who received bridging 
therapy had more severe pulmonary haemodynamics at diagnosis (mPAP 50 mmHg versus 40 
mmHg, PVR 8.8 WU versus 5 WU, p-value both <0.001) (table 8).  
CTEPH - declined surgery (patients’ choice) 
The estimated 5-year survival of patients who declined surgery was significantly worse than 
those undergoing PEA (55% versus 83%, p<0.001, figure 13A). The impact of age on long 
term outcome in patients offered surgery is shown in figure 13B-D. A survival benefit was seen 
in patients both under (p=0.036) and over 60 yrs of age (p<0.001). In more elderly patients 
above 70 years of age a trend in favour of surgery was observed (p=0.056). 
CTEPH – technically operable not offered surgery (unfit for surgery, other contributors to 
symptoms in addition to clot burden) 
Patients deemed unfit for surgery had a significantly worse survival than patients who were 
offered surgery but declined, who in turn had a significantly worse survival than patients with 
other contributors to symptoms in addition to clot burden (p<0.05, figure 14). Patients with 
other contributors to symptoms in addition to clot burden had milder pulmonary 
haemodynamics (table 11) and similar overall survival (p = 0.281, figure 15) as compared to 







CTEPH (whole cohort) 
Univariate analysis of the whole cohort identified a number of predictors of outcome (table 12). 
Independent predictors of mortality identified from multivariate analysis were: pulmonary 
endarterectomy (HR 0.38, confidence interval (CI) 0.23-0.63), DLCO (HR 0.59, CI 0.46-0.74), 
mixed venous oxygen saturation (SvO2) (HR 0.71, CI 0.57-0.87), history of cancer (HR 2.24, 
CI 1.28-3.95), chronic kidney disease (HR 2.20, CI 1.22-4.71 age (HR 1.39, CI 1.06-1.80). 
CTEPH - offered surgery 
Univariate analysis of the CTEPH-offered surgery group identified several predictors of 
outcome (table 13). Four independent predictors of survival were identified in the combined 
group of patients offered surgery: patient choice (HR 3.64, CI 1.95-6.81), SvO2 (HR 0.66, CI 
0.49-0.89), DLCO (HR 0.67, CI 0.47-0.95) and the presence of coronary artery disease (HR 
2.34, CI 1.11-4.96, table 13). 
CTEPH – surgical- operated 
Univariate analysis of the CTEPH - surgical-operated group similarly identified a number of 
predictors of outcome (table 14). Independent predictors of survival from multivariate analysis 
were age (HR 1.65, CI 1.12-2.42), SvO2 (HR 0.68, CI 0.49-0.94) and ankle swelling (HR 2.44, 
CI 1.22-4.87). In addition, it was seen that in this group of patients the waiting time from 
diagnosis to surgery did not affect survival (figure 16). 
CTEPH - declined surgery (patients’ choice) 
Receiver operator curve analysis for prediction of 3-year mortality was performed for the 3 
continuous prognostic variables identified at univariate analysis (table 15 and figure 17): DLCO 
(AUC 0.87), RAP (AUC 0.81) and SvO2 (AUC 0.85). Using median thresholds of DLCO 62%, 
RAP 11 mmHg, and SvO2 62% the sensitivity, specificity, positive predictive and negative 
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predictive values for predicting 3-year mortality were calculated as 100%, 63%, 31% and 
100%; 80%, 70%, 32% and 95%; and 90%, 60%, 30% and 97%, respectively. Kaplan-Meier 
estimates of survival in this group using the same variables (DLCO, RAP and SvO2) were also 
significant (figure 18). 
CTEPH - technically operable not operated 
Predictors identified in the univariate analysis included age, WHO FC, exercise capacity, 
pulmonary haemodynamics and co-morbidities (table 16). Univariate and multivariate analyses 
for each of the 3 sub-groups are shown in table 17. Independent predictors of outcome were 
SvO2 (HR 0.53, CI 0.38-0.76), DLCO (HR 0.54, CI 0.38-0.75), and cancer (HR 4.10, CI 2.02-
8.37). In those who declined surgery, SvO2 (HR 0.24, CI 0.12-0.51) was an independent 
predictor of survival, whilst in those unfit for surgery exercise capacity (HR 0.41, CI 0.21-0.79), 
comorbidities (cancer (HR 8.77, CI 2.76-27.81), and CKD (HR 6.98, CI 1.96-24.89), 
independently predicted outcome. In patients with other contributors to symptoms in addition to 
clot burden, cancer (HR 9.93, CI 1.98-49.85) was an independent predictor of outcome.  
CTEPH - non-surgical disease distribution 
Univariate analysis of the CTEPH - non-surgical disease distribution group also identified few 
predictors of outcome (table 18). Independent predictors of survival from multivariate analysis 
were PVR (HR 1.44, CI 1.02-2.04) and DLCO (HR 0.39, CI 0.26-0.58). 
Discussion 
To my knowledge this is the first study that primarily focuses on patients with technically 
operable CTEPH but did not undergo PEA. Patients’ choice, lack of fitness for surgery and the 
presence of other contributors to symptoms in addition to clot burden were the commonest 
reasons for patients not undergoing surgery whilst pulmonary haemodynamic severity, DLCO 
and comorbidities were independent predictors of survival. In addition, in a large cohort of 
70 
 
consecutive patients with CTEPH we have shown that long-term survival of patients 
undergoing PEA is excellent and superior to patients declining surgery, strongly favouring 
consideration of a surgical intervention in eligible patients.  
CTEPH - whole cohort 
Pulmonary endarterectomy is considered the treatment of choice for suitable patients with 
CTEPH and is thought to provide the best prospect of improved quality and quantity of life 
(Bonderman et al., 2007, Galie et al., 2015, Konstantinides, 2014). This study, conducted in a 
large cohort of consecutive patients with CTEPH, confirms the results of the international 
CTEPH registry that PEA is an independent predictor of survival (Delcroix et al., 2016). In 
operated patients it was associated with an excellent long-term outcome with an estimated 5-
year survival of 83%, similar to data from the International (Delcroix et al., 2016), Austrian 
(Nierlich et al., 2016, Skoro-Sajer et al., 2014) Spanish (Escribano-Subias et al., 2016), Italian 
(Corsico et al., 2008) and Dutch CTEPH registries (Saouti et al., 2009b). Although 482 patients 
(81%) had technically operable disease distribution, despite the proven benefits of PEA only 
272 (49% of the total cohort) underwent surgery. Previous registries reported similar 
proportions of patients who underwent PEA but provided only limited data on reasons for not 
undergoing surgery and predictors of long term outcome (Delcroix et al., 2016, Saouti et al., 
2009b, Condliffe et al., 2008). 
CTEPH – technically operable not operated 
One-hundred and seventy-six (39% of patients with technically operable disease) did not 
undergo surgery due to: patient choice (n=72), concerns regarding fitness to undergo surgery 
(n=63) or having other contributors to symptoms in addition to clot burden (n=31) where the 
benefits of surgery were felt to be minimal. The 5-year survival in patients with technically 
accessible disease not undergoing surgery was 53%, significantly better than historical studies 
of patients with CTEPH treated with anticoagulation alone (Lewczuk et al., 2001, Riedel M, 
1982). Survival was related to the rationale underpinning the treatment decision with those 
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declining surgery having a superior survival to those who were deemed unfit for surgery. Not 
only did markers of disease severity such as SvO2 and DLCO independently predict survival but 
also the presence of comorbidities, emphasising the impact of conditions out with the 
pulmonary vasculature when making treatment decisions. 
CTEPH - declined surgery (patients’ choice) 
The proportion of patients with technically operable disease who were offered surgery (n=344) 
but declined (n=72, 21%) is larger than previously noted in other registries and may reflect the 
consecutively-enrolled nature of my study (Delcroix et al., 2016, Saouti et al., 2009b, Condliffe 
et al., 2008). These data highlight the importance of patients being referred for assessment 
and counselling by a PEA surgeon and experienced multi-professional team. In patients who 
declined surgery, the severity of pulmonary haemodynamics and DLCO predicted outcome, with 
median thresholds for DLCO, right atrial pressure, and SvO2 having negative predictive values 
for 3-year mortality >95%. For a selected cohort of patients, who, despite counselling decline 
surgery this information may be useful, although it must also be emphasised that quality of life 
benefits in the majority of patients are greater with surgery (Thakrar et al., 2013, Genta et al., 
2005). In contrast, patients with severe haemodynamics assessed to be good surgical 
candidates may find data highlighting a poor prognosis in the absence of a surgical 
intervention an aid to decision-making. 
This study has demonstrated a significantly superior survival in patients with CTEPH who were 
offered surgery and underwent PEA compared to those who declined. Although patients 
declining surgery were older, with a poorer exercise capacity and more comorbidities, 
declining surgery due to patients’ choice was an independent predictor of a worse outcome i.e. 
even when important other factors such as patient age and comorbidities were taken into 
account patients’ choice to decline surgery predicted a significantly worse outcome. In patients 
who declined compared to those who underwent surgery, there was a female predominance 
(Hurdman et al., 2012) and gender specific factors related to risk-taking may play a role 
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(Harris, 2006). Given the findings of this study and the benefit of PEA more work is required to 
understand factors underlying decisions to decline surgery. 
Unfit for surgery 
In expert hands PEA has a perioperative mortality of <5% and offers the best chance of longer 
term survival, but requires careful assessment of risks versus benefits for individual patients 
(Madani et al., 2012, Delcroix et al., 2016). A total of 63 patients (14% of those with technically 
operable disease) were deemed unfit for surgery by the MDT. These patients had a 
significantly poorer survival than those declining surgery. Alternative interventions to surgery 
such as balloon pulmonary angioplasty may appear attractive in these patients, but the 
presence of significant comorbidities may be primary determinants of survival. A meticulous 
assessment balancing the potential symptomatic benefit versus the risks of such interventions 
is therefore paramount where mortality benefit is not clear. 
CTEPH - non-surgical disease distribution 
Nineteen percent of all patients were deemed to have non-surgical disease distribution. This 
proportion is similar to the International CTEPH registry (20%) (Delcroix et al., 2016) but less 
than the UK (32%) (Condliffe et al., 2008) and Dutch (26%) (Saouti et al., 2009a) registries. 
This may reflect an increasing willingness amongst surgeons to operate on patients with 
disease that would previously have been considered too distal to benefit from surgery. Indeed 
a number of centres have shown that outcomes in patients with Type 3 disease (more distal) in 
expert hands are now similar to more proximal disease (Type 1 and 2) (Madani et al., 2012) 
(D'Armini et al., 2014). I noted a female predominance, an increased incidence of thyroid 
disease and splenectomy and reduced incidence of VTE in this group (table 5) in keeping with 
previous reports (Corsico et al., 2008). 
CTEPH - surgical operated: timing of surgery and pulmonary vasodilator therapy 
The mean time from diagnosis to PEA surgery was 290±175 days, longer than previously 
reported studies (Delcroix et al., 2016, Skoro-Sajer et al., 2014, Condliffe et al., 2008, Mayer et 
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al., 2011) but in line with waiting times for surgery in the UK during the duration of this study 
(Gibbs, 2017) although, UK waiting times are now falling (Gibbs, 2018). In keeping with data 
from the International CTEPH registry, the duration of delay did not impact on long-term 
survival (figure 16) (Delcroix et al., 2016). A large number of patients were bridged to PEA with 
off-label PAH–specific therapies (74%). Although there is no published evidence to support 
this practice, this may reflect the longer time from referral to surgery in the UK during the study 
period as compared to that reported in the International CTEPH registry (Delcroix et al., 2016). 
Importantly, bridging therapy had no effect on time to referral or to surgery (table 8). Patients 
receiving bridging therapy in the present study had similar haemodynamics to those who 
received bridging therapy in the International CTEPH registry, while patients who were not 
bridged to surgery had milder haemodynamics than those in the International registry (table 8) 
(Delcroix et al., 2016). Importantly, in this study receiving bridging therapy was not associated 
with adverse outcome at univariate analysis (HR 0.772, CI 0.39-1.51, p = 0.448). 
Limitations 
This study predates the availability of balloon angioplasty and riociguat therapy in the UK and 
therefore the impact of these interventions and their potential benefits cannot be assessed. 
Although patient-specific data were enriched by retrospective case note review and 
interrogation of databases, this resulted in higher levels of data completeness than in other 
contemporary registries. Furthermore, the consecutive nature of enrolment in the ASPIRE 
registry reduces recruitment bias associated with previous non-consecutively enrolled studies. 
This study provides no data on the reasons for patients declining surgery. Although the results 
suggest that surgery improves survival in patients with technically operable disease who were 
offered surgery, patients judged to be unfit for surgery by the MDT and those in whom there 
were other contributors to symptoms in addition to clot burden were excluded. For the 
individual patient factors including age and comorbidities will influence outcome following 




This study report results from a large consecutively enrolled registry of patients with CTEPH. I 
have been able to compare characteristics and have also identified predictors of survival in 
patients who did not undergo surgery despite having technically operable disease. My data 
has shown that survival of patients undergoing PEA is excellent and superior to patients 
declining surgery and strongly favours consideration of a surgical intervention in eligible 
patients. More work is required to understand factors influencing decision making in CTEPH 
and to ensure that patients are counselled and supported to make informed decisions. 
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Table 6: Baseline characteristics of patients with CTEPH 










Number (%) 550 (100) 272 (49) 176 (32) 102 (19) 
Age (years) 63 (15) 58 (14) #, + 69 (14) *,$ 65 (15) * 
Gender (%Female) 50 45 +,# 50* 62* 
BMI (kg/m2) 29 (7) 30 (7) 29 (8) 29 (6) 
Duration of symptoms (%, <1 
year/1-2 years/2-5 years/>5 
years/not clear) 
15/38/24/16/8 14/40/27/16/3 17/35/19/14/14 12/33/28/18/9 
WHO FC (I/II vs III/IV) 11/89 13/87+ 11/89 3/97* 
ISWD (m) 189 (177) 232 (185)#, * 142 (157) * 155 (160) * 
RAP (mmHg) 11 (5) 11 (5) 11 (6) 12 (5) 
mPAP (mmHg) 46 (11) 47 (11) # 43 (11)  *, + 48 (12) # 
CI (L/min/m2) 2.5 (0.8) 2.5 (0.7) 2.6 (0.8) 2.5 (0.8) 
PCWP (mm of Hg) 12 (5) 12 (4) 12 (6) 11 (4) 
PVR (Wood Units) 7.7 (4.3) 7.7 (4) 7 (4.6) + 8.7 (4.5) # 
SvO2 (%) 61 (8) 61 (8) 61 (9) 61 (9) 
FEV1 (% predicted) 80 (35) 83 (43) # 75 (23)  * 80 (24) 
DLCO (% predicted) 61 (17) 65 (15) # 55 (19)  *,+ 61 (17)# 
History of acute VTE (%) 71 74 + 74+ 57*, # 
IVC filter (%) 3 3 5 1 
Thrombophilia (%) 5 6 3 3 
History of cancer (%) 11 6 #,+ 15* 15* 
Smoking (%) 38 38 43 30 
Obesity (%) 36 39 32 32 
Splenectomy 5 3 + 3 + 12 *,# 
Thyroid disorder (%) 12 8 + 14 18 * 
V-A shunt/PPM infection (%) 2 2 0 4 
IBD (%) 1 1 2 2 
CAD (%) 11 10 14 7 
LV dysfunction (%) 4 2 # 8 *, + 2 # 
Valvular heart disease(%) 2 2 2 2 
CKD (%) 7 3 # 13 * 6 
COPD (%) 19 13 # 30 * 19 
PH therapy following 
diagnosis (%) 76 74
+ 72+ 86*,# 
 
Definition of abbreviations: n = number of patients; BMI = body mass index; WHO FC = World Health Organization functional class; ISWD = 
incremental shuttle walk distance; RAP = right atrial pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; PCWP = 
pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; SvO2  = mixed venous oxygen saturation; FEV1 = forced 
expiratory volume in one second; DLCO = diffusing capacity of lung for carbon monoxide; VTE = venous thromboembolism; IVC = inferior vena 
cava; PE = pulmonary embolism; V-A = ventricular atrial; PPM = permanent pacemaker; IBD = inflammatory bowel disease; CAD = coronary 
artery disease; LV = left ventricle; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; PH = pulmonary 
hypertension; 
Values are mean (standard deviation) or percentage unless otherwise indicated. 
*:  p < 0.05 in comparison to CTEPH-operated. 
#: p < 0.05 in comparison to CTEPH-technically-operable-not operated. 
+: p < 0.05 in comparison to CTEPH-non-surgical-disease-distribution. 
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Table 7: Detailed breakdown of the PH specific targeted therapy used in patients with CTEPH 
 
PH therapy Number of patients Percentage 
PDE-5i only 315 76 
ERA only 49 13 
PGI2 only 22 5 
PDE-5i+ERA 18 4 
PDE-5i+PGI2 12 3 
 
Definition of abbreviations: PH = pulmonary hypertension; PDE-5i = phosphodiesterase 5 inhibitors; ERA = endothelin receptor antagonists; 



























Table 8: Baseline characteristics in patients undergoing PEA who received bridging therapy 




No bridging therapy 
n=72 (26%) p-value 
Age 60 (14) 55 (14) 0.014 
Gender (%, Female) 44 47 0.672 
WHO FC (I/II vs III/IV) % 6/94 35/65 <0.001 
ISWD (m) 183 (143) 366 (220) <0.001 
RAP (mmHg) 11 (5) 8 (5) <0.001 
mPAP (mmHg) 50 (10) 40 (11) <0.001 
CI (L/min/m2) 2.4 (0.6) 2.9 (0.7) <0.001 
PCWP (mmHg) 11 (4) 12 (4) 0.166 
PVR (Wood Units) 8.8 (4) 5 (3) <0.001 
SvO2 (%) 59 (8) 66 (7) <0.001 
DLCO (%) 64 (15) 68 (16) 0.032 
H/o VTE (%) 73 74 0.920 
H/o Cancer (%) 7 6 0.751 
CAD (%) 12 7 0.257 
LV dysfunction (%) 1 6 0.026 
CKD (%) 3 1 0.448 
COPD (%) 15 7 0.088 
Time to Surgery (days) 291 (158) 289 (221) 0.965 
 
Definition of abbreviations: n = number of patients; WHO FC=World Health Organization functional class; ISWD= Incremental shuttle walk 
distance; RAP=right atrial pressure; mPA=mean pulmonary arterial pressure; CI=cardiac index; PCWP=pulmonary capillary wedge pressure; 
PVR=pulmonary vascular resistance; SvO2=mixed venous oxygen saturation; DLCO= diffusing capacity of lung for carbon monoxide; 
VTE=venous thromboembolism; CAD=coronary artery disease; LV=left ventricle; CKD=chronic kidney disease; COPD=chronic obstructive 
pulmonary disease;  
Values are mean (standard deviation) or percentage unless otherwise indicated. 



















Table 9: Baseline characteristics of CTEPH-operated group versus patients who declined 











Number of patients 272 72  
Age (years) 58 (14) 68 (16) <0.001 
Gender (%, Female ) 45 63 0.007 
BMI 30 (7) 29 (7) 0.485 
WHO FC (I/II Vs II/IV) 13/87 17/83 0.462 
Duration of symptoms (<1 year/1-
2 years/2-5 years/>5 years/not 
clear) 
14/40/27/16/3 22/38/17/11/13 0.009 
ISWD (m) 232 (185) 169 (177) 0.009 
RAP (mmHg) 11 (5) 12 (6) 0.192 
mPAP (mmHg) 47 (11) 46 (10) 0.360 
CI (L/min/m2) 2.5 (0.8) 2.6 (0.8) 0.305 
PCWP (mmHg) 12 (4) 12 (5) 0.667 
PVR (Wood Units) 7.7 (4) 8 (4) 0.767 
SvO2 (%) 61 (8) 61 (9) 0.610 
FEV1 (% predicted) 83 (43) 82 (21) 0.714 
DLCO (% predicted) 65 (15) 61 (17) 0.084 
History of VTE (%) 74 69 0.489 
History of cancer (%) 6 6 0.827 
Smoking (%) 38 35 0.664 
Obesity (%) 39 26 0.048 
CAD (%) 11 8 0.620 
LV dysfunction (%) 2 6 0.131 
CKD (%) 3 14 <0.001 
COPD (%) 13 17 0.356 
PH therapy following diagnosis 
(%) 74 75 0.849 
 
Definition of abbreviations: n = number of patients; BMI = body mass index; WHO FC = World Health Organization functional class; ISWD = 
incremental shuttle walk distance; RAP = right atrial pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; PCWP = 
pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; SvO2  = mixed venous oxygen saturation; FEV1 = forced 
expiratory volume in one second; DLCO (%) = diffusion capacity of lung for carbon monoxide; VTE = venous thromboembolism; CAD = 
coronary artery disease; LV = left ventricle; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; PH = pulmonary 
hypertension; 
Values are mean (standard deviation) or percentage unless otherwise indicated. 








Table 10: Baseline characteristics in CTEPH-technically-operable-not-operated sub-groups 
(declined surgery (patient choice), unfit for surgery and CTEPH where symptoms may be 




Unfit for surgery 
 
Other contributors to 
symptoms in addition 
to clot burden 
Number of patients 72 63 31 
Age (years) 68 (16) 70 (12) 69 (12) 
Gender (%, Female) 63 41 45 
BMI 29 (7) 29 (8) 32 (8) 
WHO FC (I/II vs III/IV) 17/83 * 3/97 # 19/81 
Duration of symptoms (<1 
year/1-2 years/2-5 years/>5 
years/not clear) 
22/38/17/11/13 11/37/18/21/14 19/36/23/10/7 
ISWD (m) 169 (177) * 95 (119) #,+ 210 (162) * 
RAP (mmHg) 12 (6) + 11 (6) 8 (3) # 
mPAP(mmHg) 46 (10) + 46 (10) + 31 (7) #, * 
CI (L/min/m2) 2.6 (0.8) + 2.4 (0.7) + 3.3 (0.6) #,* 
PCWP (mmHg) 12 (5) 13 (6) 13 (6) 
PVR (Wood Units) 8 (4) + 8.5 (5) + 3 (1.4) # 
SvO2 (%) 61 (9) + 59 (9) + 68 (6) #, * 
FEV1 (% predicted) 82 (21) * 66 (22) #, + 81 (23) * 
DLCO (% predicted) 61 (17) * 43 (16) #, + 65 (18) * 
History of VTE (%) 70 76 90 
IVC filter (%) 4 8 0 
Thrombophilia (%) 7 2 0 
History of cancer (%) 6+ 19 32 # 
Smoking (%) 35 * 62 #, + 36 * 
Obesity (%) 26 30 45 
CAD (%) 8 21 13 
LV dysfunction (%) 6 13 10 
Valvular heart disease (%) 0 3 3 
CKD (%) 14 13 10 
COPD (%) 17 * 48 # 29 
PH therapy following 
diagnosis (%) 
75 *, + 87 #, + 13 #, * 
 
Definition of abbreviations: n = number of patients; BMI = body mass index; WHO FC = World Health Organization functional class; ISWD = 
incremental shuttle walk distance; RAP = right atrial pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; PCWP = 
pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; SvO2  = mixed venous oxygen saturation; FEV1 = forced 
expiratory volume in one second; DLCO = diffusing capacity of lung for carbon monoxide; VTE = venous thromboembolism; IVC = inferior vena 
cava; PE = pulmonary embolism; CAD = coronary artery disease; LV = left ventricle; CKD = chronic kidney disease; COPD = chronic 
obstructive pulmonary disease; PH = pulmonary hypertension; 
Values are mean (standard deviation) or percentage unless otherwise indicated. 
Mean (standard deviation) or percentage presented. 
#: p < 0.05 in comparison to CTEPH-technically-operable-not operated (patient choice). 
*:  p < 0.05 in comparison to CTEPH-technically-operable-not-operated (unfit for surgery). 





Table 11: Baseline characteristics of CTEPH-operated group versus patients with other 




to symptoms in 




Number 272 (49) 31  
Age (years) 58 (14) 69 (12) <0.001 
Gender (%, Female) 45 45 0.943 
BMI 30 (7) 32 (8) 0.109 
WHO FC (I/II vs III/IV) 13/87 19/81 0.355 
Duration of symptoms (<1 
year/1-2 years/2-5 years/>5 
years/not clear) 
14/40/27/16/3 19/36/23/10/7 0.025 
ISWD (m) 232 (185) 210 (162) 0.492 
RAP (mmHg) 11 (5) 8 (3) 0.020 
mPAP(mmHg) 47 (11) 31 (7) <0.001 
CI (L/min/m2) 2.5 (0.7) 3.3 (0.6) <0.001 
PCWP (mmHg) 12 (4) 13 (6) 0.154 
PVR (Wood Units) 7.7 (4) 3 (1.4) <0.001 
SvO2 (%) 61 (8) 68 (6) <0.001 
FEV1 (% predicted) 83 (43) 81 (23) 0.624 
DLCO (% predicted) 65 (15) 65 (18) 0.928 
History of VTE (%) 74 90 0.040 
IVC filter (%) 3 0 0.366 
Thrombophilia (%) 6 0 0.165 
History of cancer (%) 6 32 <0.001 
Smoking (%) 38 36 0.826 
Obesity (%) 36 45 0.504 
CAD (%) 10 13 0.654 
LV dysfunction (%) 2 10 0.020 
Valvular heart disease (%) 2 3 0.599 
CKD (%) 3 10 0.036 
COPD (%) 13 29 0.012 
PH therapy following 
diagnosis (%) 74 13 <0.001 
 
Definition of abbreviations: n = number of patients; BMI = body mass index; WHO FC = World Health Organization functional class; ISWD = 
incremental shuttle walk distance; RAP = right atrial pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; PCWP = 
pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; SvO2  = mixed venous oxygen saturation; FEV1 = forced 
expiratory volume in one second; DLCO= diffusing capacity of lung for carbon monoxide; VTE = venous thromboembolism; IVC = inferior vena 
cava; PE = pulmonary embolism; CAD = coronary artery disease; LV = left ventricle; CKD = chronic kidney disease; COPD = chronic 
obstructive pulmonary disease; PH = pulmonary hypertension; 
Values are mean (standard deviation) or percentage unless otherwise indicated. 






Table 12: Cox regression survival analysis for CTEPH-whole cohort 
 Univariate analysis Multivariate analysis 
Covariates  HR 95% CI p- 
value 
HR 95% CI p-
value 
Age*  /15 years 1.68 1.40-2.02 <0.001 1.39 1.06-1.80 0.016 
BMI* /7 kg/m2 0.82 0.68-0.99 0.046    
WHO FC I/II or III/IV 
Ref= I/II 
2.20 1.12-4.30 0.021    
ISWD* /177 m 0.51 0.41-0.63 <0.001    
RAP* /5 mmHg 1.30 1.14-1.49 <0.001    
CI* /0.8 L/min/m2 0.75 0.64-0.88 <0.001    
PVR* /4.3 Wood 
Units  
1.36 1.16-1.60 <0.001    
SvO2* /8% 0.66 0.57-0.76 <0.001 0.71 0.57-0.87 0.001 
FEV1* /35% 0.65 0.49-0.86 0.002    
DLCO* /17% 0.52 0.44-0.62 <0.001 0.59 0.46-0.74 <0.001 
VTE ref = absent 0.70 0.51-0.95 0.020    
Cancer ref = absent 2.33 1.58-3.45 <0.001 2.24 1.28-3.95 0.005 
Obesity ref = absent 0.68 0.49-0.95 0.023    
Thyroid 
disorders 
ref = absent 1.35 0.88-2.06 0.166    
CAD ref = absent 2.17 1.47-3.18 <0.001    
LVF ref = absent 1.77 0.86-3.48 0.096    
CKD ref = absent 2.33 1.44-3.77 0.001 2.20 1.22-4.71 0.021 
PEA ref = not 
performed 
0.31 0.22-0.43 <0.001 0.38 0.23-0.63 <0.001 
 
Data shown for univariate analysis where p < 0.20, 72 variables were imported into univariate analysis. 
Definition of abbreviations: ref = reference parameter; BMI = body mass index; WHO FC = World Health Organization functional class; ISWD 
= incremental shuttle walk distance; RAP = right atrial pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; PVR = 
pulmonary vascular resistance; SvO2  = mixed venous oxygen saturation; FEV1 = forced expiratory volume in one second; DLCO = diffusing 
capacity of lung for carbon monoxide; VTE = venous thromboembolism; CAD = coronary artery disease; LVF = left ventricle; failure; CKD = 
chronic kidney disease;  







Table 13: Cox regression survival analysis in CTEPH-technically-operable who were offered 
surgery (operated group and declined surgery (patient choice) sub-groups) 
 
 Univariate analysis Multivariate analysis 
Covariates  HR 95% CI p- 
value 
HR 95% CI p-
value 
Age*  /15 years 1.71 1.30-2.25 <0.001    
WHO FC I/II or II/IV ref = I/II 3.98 1.25-12.65 0.019    
Cardiac arrhythmia ref = absent 2.16 1.03-4.53 0.043    
ISWD*  /185 m 0.56 0.41-0.75 <0.001    
RAP* /6mmHg 1.57 1.25-1.98 <0.001    
PVR* /4 Wood Units 1.39 1.08-1.78 0.009    
SvO2* /8% 0.62 0.49-0.77 <0.001 0.66 0.49-0.89 0.006 
DLCO* /16% 0.56 0.42-0.75 <0.001 0.67 0.47-0.95 0.025 
VTE ref = absent 0.62 0.39-0.98 0.045    
Cancer ref = absent 1.77 0.85-3.69 0.127    
Obesity ref = absent 0.55 0.33-10.92 0.024    
Thyroid disorders ref = absent 1.65 0.87-3.15 0.122    
CAD ref = absent 2.21 1.24-3.94 0.007 2.34 1.11-4.96 0.026 
CKD ref = absent 1.90 0.82-4.38 0.132    
Patient choice ref = surgery 2.56 1.57-4.16 <0.001 3.64 1.95-6.81 <0.001 
 
Data shown for univariate analysis where p < 0.20, 72 variables were imported into univariate analysis. 
Definition of abbreviations: ref = reference parameter; WHO FC = World Health Organization functional class; ISWD = incremental shuttle 
walk distance; RAP = right atrial pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; PVR = pulmonary vascular 
resistance; SvO2  = mixed venous oxygen saturation; FEV1 = forced expiratory volume in one second; DLCO = diffusing capacity of lung for 
carbon monoxide; VTE = venous thromboembolism; CAD = coronary artery disease; CKD = chronic kidney disease; PEA = pulmonary 
endarterectomy; 



















Table 14: Cox regression survival analysis of CTEPH-operated group 
 
 Univariate analysis Multivariate analysis 
Covariates  HR 95% CI  p-value HR 95% CI p-value 
Age* /14 years 1.65 1.19-2.29 0.003 1.65 1.12-2.42 0.011 
WHO FC I/II or III/IV Ref= I/II 2.47 0.77 —7.93 0.130    
ISWD* /185 m 0.57 0.40-0.82 0.002    
RAP* /5mmHg 1.35 1.06-1.72 0.017    
mPAP* /11 mmHg 1.22 0.91-1.62 0.189    
CI* /0.8 L/min/m2 0.67 0.45-0.95 0.025    
SvO2* /8% 0.66 0.450-0.86 0.002 0.68 0.49-0.94 0.019 
FEV1* /43% 0.43 0.21-0.86 0.017    
DLCO* /15% 0.63 0.44-0.89 0.008    
VTE Ref= absent 0.55 0.31-0.96 0.036    
Cancer Ref = absent 2.07 0.88-4.86 0.096    
CAD Ref = absent 2.54 1.30-4.96 0.006    
Ankle swelling Ref = absent 2.06 1.19-3.57 0.010 2.44 1.22-4.87 0.012 
Cardiac  
arrhythmia Ref = absent 2.56 1.08-6.07 0.033    
 
 
Data shown for univariate analysis where p< 0.20, 75 variables were imported into univariate analysis. 
Definition of abbreviations: WHO FC = World Health Organization functional class; ISWD = incremental shuttle walk distance; RAP=right atrial 
pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; SvO2  = mixed venous oxygen saturation; FEV1 = forced expiratory 
volume in one second; DLCO = diffusing capacity of lung for carbon monoxide; VTE = venous thromboembolism; CAD = coronary artery 
disease;  






















Table 15: Receiver operating characteristics analysis presenting area under the curve, 
sensitivity and specificity, positive and negative predictive values in the CTEPH-technically 














(≥ 62% vs < 62%) 
0.87 100 63 31 100 
RAP 11mmHg (≤ 11mmHg vs > 11 
mmHg) 
0.81 80 70 32 95 
Svo2 62% 
(> 62 % vs ≤ 62%) 
0.85 90 60 30 97 
 
 
Definition of abbreviations: AUC = area under curve; DLCO = diffusing capacity of lung for carbon monoxide; RAP = right atrial pressure; SvO2  




















Table 16: Cox regression survival analysis of CTEPH-technically-operable-not-operated group 
 
 Univariate analysis Multivariate analysis 
Covariates  HR 95% CI p- value HR 95% CI p-value 
Age* /14 years 1.33 1.02-1.74 0.034    
WHO FC I/II or III/IV (ref = I/II) 2.80 0.88-8.95 0.081    
ISWD* /160 m 0.59 0.39-0.79 0.001    
RAP* /5 mmHg 1.38 1.10-1.73 0.005    
CI* /0.8L/min/m2 0.62 0.46-0.82 0.001    
PVR* /4.6Wood Units 1.59 1.27-2.00 <0.001    
SvO2* /9% 0.56 0.44-0.72 <0.001 0.53 0.38-0.76 <0.001 
DLCO* /19 % 0.53 0.39-0.71 <0.001 0.54 0.38-0.75 <0.001 
Cancer Ref=absent 2.98 1.72-5.15 <0.001 4.10 2.02-8.37 <0.001 
CAD Ref=absent 2.18 1.21-3.95 0.010    
CKD Ref=absent 1.89 1.03-3.48 0.041    
 
Data shown for univariate analysis where p < 0.20, 71 variables were imported into univariate analysis. 
Definition of abbreviations: Ref= reference parameter; WHO FC = World Health Organization functional class; ISWD = incremental shuttle 
walk distance; RAP = right atrial pressure; CI = cardiac index; PVR = pulmonary vascular resistance; SvO2  = mixed venous oxygen saturation; 
DLCO= diffusing capacity of lung for carbon monoxide; CAD = coronary artery disease; CKD = chronic kidney disease;  















Table 17: Cox regression survival analysis for CTEPH-technically-operable-not-operated: 
patient choice, unfit for surgery and other contributors to symptoms in addition to clot burden 
sub-groups 
 
Patient choice Univariate analysis Multivariate analysis 
Covariates  HR 95% CI p-value HR 95% CI p-value 
Age* /16 years 1.40 0.88-2.25 0.160    
WHO FC I/II or III/IV ref = I/II 27.42 0.27-2732.21 0.158    
ISWD* /177 m 0.71 0.42-1.19 0.187    
RAP* /6mmHg 1.83 1.23-2.73 0.003    
CI* /0.8 L/min/m2 0.70 0.44-1.10 0.121    
PVR* /4.25 Wood Units 1.58 1.01-2.49 0.047    
SvO2* /9% 0.53 0.34-0.82 0.004 0.24 0.12-0.51 <0.001 
DLCO* /17% 0.52 0.31-0.85 0.009    
Thyroid 
disorder ref = absent 1.91 0.74-4.91 0.182    
CAD ref = absent 2.28 0.67-7.77 0.189    
Unfit for surgery Univariate analysis Multivariate analysis 
Covariates  HR 95% CI p-value HR 95% CI p-value 
ISWD* /114 m 0.65 0.42-0.99 0.046 0.41 0.21-0.79 0.008 
RAP* /6 mmHg 1.27 0.89-1.82 0.185    
CI* /0.7 L/min/m2 0.66 0.44-1.01 0.054    
PVR* /4.94 Wood Units 1.34 0.94-1.88 0.102    
SvO2* /9% 0.64 0.44-0.92 0.016    
DLCO* /17 % 0.75 0.51-1.09 0.133    
Cancer ref = absent 2.96 1.47-5.97 0.002 8.77 2.76-27.81 <0.001 
CKD ref = absent 2.46 1.06-5.68 0.035 6.98 1.96-24.89 0.003 
Other contributors to symptoms in 
addition to clot burden Univariate analysis Multivariate analysis 
Covariates   HR 95% CI p-value HR 95% CI p-value 
Age* /12 years 2.53 0.97-6.81 0.067    
WHO FC I/II or III/IV ref = I/II 4.76 01.06-21.33 0.041    
ISWD* /162m 0.55 0.23-1.35 0.193    
Cancer ref = absent 6.63 1.98-49.85 0.005 9.93 1.98-49.85 0.005 
LV dysfunction ref = absent 4.55 0.89-23.08 0.067    
 
Data shown for univariate analysis where p < 0.20, 71 variables were imported into univariate analysis. 
Definition of abbreviations: ref = reference parameter; WHO FC = Word Health Organization functional class; ISWD = incremental shuttle walk 
distance; RAP = right atrial pressure; CI = cardiac index; PVR = pulmonary vascular resistance; SvO2 = mixed venous oxygen saturation;  
DLCO = diffusing capacity of lung for carbon monoxide ; CAD = coronary artery disease; CKD = chronic kidney disease; VTE = venous 
thromboembolism; LV = left ventricular; 
* These variables are scaled so that the hazard ratio (HR) is the change by one standard deviation (SD). 
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Table 18: Cox regression survival analysis of patients with CTEPH-non-surgical disease 
distribution 
 Univariate analysis Multivariate Analysis 
Covariates  HR 95% CI p-value HR 95% CI p-value 
Age* /19 years 1.62 0.98-2.66 0.059    
ISWD* /160m 0.55 0.36-0.85 0.007    
PVR* 4.5 WU 1.27 0.95-1.71 0.101 1.44 1.02-2.04 0.038 
SvO2* /9% 0.65 0.45-0.91 0.011    
DLCO* /17% 0.52 0.38-0.72 <0.001 0.39 0.26-0.58 <0.001 
 
 
Data shown for univariate analysis where p < 0.20, 71 variables were imported into univariate analysis. 
Definition of abbreviations: ref = reference parameter; WHO FC = World Health Organization functional class; 
ISWD = Incremental shuttle walk distance; PVR = pulmonary vascular resistance; SvO2 = mixed venous oxygen saturation; DLCO= diffusing 
capacity of lung for carbon monoxide; WHO FC = World Health Organization functional class; 




















n = 600 
      
Patients excluded 
 
n = 50 
 
      Reasons for exclusion: 
• CTED (10) 
• CTEPH, unknown classification (5) 
• Pulmonary sarcoma (2) 
• No RHC done (21) 
• Others (12) 
 
 








n = 102 
    
       
CTEPH-surgical 
 




n = 272 
    






n = 176 
      
       
Declined surgery 
(Patient choice) 
n = 72 
 




n = 63 
 
CTEPH with other 
contributors to 
symptoms in addition 
to clot burden 
n = 31 
 
Reason for decision not 
clear 
n = 10 
 
Definition of abbreviations: CTEPH = chronic thromboembolic pulmonary hypertension; CTED = chronic thromboembolic disease; PH = 







Figure 8: The number of patients newly diagnosed with CTEPH at the study centre each year 





















Figure 9: Kaplan-Meier estimates of survival from date of diagnosis in CTEPH- operated, 
















Figure 10: Kaplan-Meier estimates of survival from date of diagnosis in CTEPH patients, 








Figure 11: Kaplan-Meier estimates of survival from date of diagnosis in patients with CTEPH 
based on their post-operative pulmonary vascular resistance on right heart catheterization, log-
















Figure 12: Kaplan-Meier estimates of survival from date of diagnosis in operated patients, 













Figure 13: Kaplan-Meier estimates of survival from date of diagnosis comparing outcomes in 
patients with technically operable CTEPH who were offered surgery and underwent PEA 
versus patients who declined surgery (patient choice). A: all patients B: patients < 60 yrs, C: 
patients ≥ 60 years, D: patients ≥70 years 
         A                B 
 














Figure 14: Kaplan-Meier estimates of survival from date of diagnosis comparing outcomes in 
patients with technically operable CTEPH who declined surgery (patient choice) were 














Figure 15: Kaplan-Meier estimates of survival from date of diagnosis comparing outcomes in 
patients with CTEPH who have undergone PEA and other contributors to symptoms in addition 
















Figure 16: Kaplan-Meier estimates of survival from date of diagnosis in patients with CTEPH 












Figure 17: Accuracy of prognostic variables at three years in patients with technically operable 
disease who declined surgery: diffusing capacity of lung for carbon monoxide right atrial 
pressure and mixed venous oxygen saturation 
 













Figure 18: Kaplan-Meier estimates of survival from date of diagnosis in patients with 
technically operable CTEPH who declined surgery due to patient choice based on their (A) 
baseline gas transfer, (B) mixed venous oxygen saturations and (C) right atrial pressure 
           A                     B 
c 
                   C 
























Chapter 4: Successful outcomes in chronic 
thromboembolic pulmonary hypertension using 









Chronic thromboembolic pulmonary hypertension (CTEPH) is potentially curable by pulmonary 
endarterectomy. Therefore, identification of patients suitable for surgery is of utmost 
importance in the treatment of the disease. Current guidelines recommend conventional 
pulmonary angiography as the final step in the diagnostic pathway. The aim of this study was 
to identify whether a non-invasive imaging approach in conjunction with right heart 
catheterisation could be used to aid treatment decisions in CTEPH with comparable outcomes 
to the published literature using conventional pulmonary angiography techniques. 
Methods 
Imaging data was analysed for CTEPH patients identified from the ASPIRE Registry between 
2001 and 2014.  
Results 
A total of 507 patients were identified. The mean age was 63±15 years, with 49% female, 89% 
WHO functional class III/IV, 72% having a previous history of venous thromboembolism, mean 
pulmonary artery pressure 46±11mmHg and pulmonary vascular resistance 7.6±4.2 WU. Of 
the patients, 94% underwent multimodality imaging, 96% CT-pulmonary-angiography, 84% 
perfusion-MR-angiography, 78% ventilation-perfusion or perfusion-only-lung-imaging, and 2% 
conventional pulmonary angiography.  82% (n=418) of patients identified with CTEPH had 
technically operable disease. Of this 61% (n=256) of the patients underwent PEA surgery with 






By using a non-invasive multimodality imaging approach in CTEPH a proportion of patients 
with technically operable disease can be identified as compared to approaches based on 
conventional pulmonary angiography. In addition, selection of patients for surgery using a non-
invasive imaging approach was associated with a low peri-operative mortality. These results 
highlight the value of a non-invasive multi-modality imaging approach to assess patients with 




Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a form of pulmonary 
hypertension which is potentially curable by pulmonary endarterectomy. In majority of cases it 
follows an acute episode of pulmonary embolism but it can also present as an unexplained 
pulmonary hypertension with no previous history of venous thromboembolism  (Pepke-Zaba et 
al., 2011). Characteristic imaging features of CTEPH include the presence of complete or 
partial vessel obstruction, luminal thrombus, webs, stenosis, post-stenotic dilatation and 
mosaic perfusion (Lang et al., 2010). 
Traditionally, the assessment of patients with suspected CTEPH was based on initial 
ventilation-perfusion lung scanning with subsequent conventional pulmonary angiography and 
right heart catheterisation. Many of the defects demonstrated on conventional pulmonary 
angiography can be demonstrated on CT-pulmonary angiography (CTPA) (Ley et al., 2012). 
Over recent years there has been increased use of CTPA in the diagnosis of CTEPH, however 
conventional pulmonary angiography remains a common modality. A study done by Pepke-
Zaba et al. reported that at least 63% of patients enrolled in a large international CTEPH 
registry had undergone conventional pulmonary angiography (Pepke-Zaba et al., 2011). MR 
imaging techniques have also been shown to be effective at imaging the pulmonary arterial 
tree. 3D-MR perfusion imaging has been demonstrated to be as sensitive as standard isotope 
perfusion imaging (Rajaram et al., 2013, Rajaram et al., 2012). Although current guidelines 
recommend CTPA following initial ventilation-perfusion imaging, conventional pulmonary 
angiography is recommended as the final step in the diagnostic pathway in the work up of 
patients with CTEPH (Galie et al., 2015). The aim of this study was to assess the outcome of 
patients identified with CTEPH using a first-line non-invasive multimodality imaging approach. 
Specifically, I wished to compare the percentages of patients with CTEPH who were identified 
as having surgically accessible disease and their peri-operative outcomes with contemporary 
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registry data including the International CTEPH Registry, to establish whether such a non-
invasive imaging approach could be advocated for patients with CTEPH. 
Methods 
Data from the ASPIRE registry for consecutive treatment-naïve patients diagnosed with 
CTEPH between 2001 and 2014 at the Sheffield Pulmonary Vascular Disease Unit was 
reviewed. Patients with suspected CTEPH underwent first line multimodality imaging with 
ventilation perfusion or perfusion lung imaging and/or 3D MR and MR angiography and/or 
CTPA. Conventional pulmonary angiography (digital subtraction angiography) was only 
performed if diagnostic quality imaging was not available from 2 imaging modalities. The rest 
of the methods including statistical analysis have been previously described in Chapter 2.  
Results 
A total of 507 patients with CTEPH were identified (figure 19): mean age 63±15 years, 49% 
female, 89% WHO functional class III/IV with 72% having a previous history of venous 
thromboembolism. At right heart catheterisation, mean right atrial pressure was 11±5mmHg, 
mean pulmonary artery pressure 46±11mmHg, cardiac index 2.6±0.7 L.min.m-2, pulmonary 
vascular resistance 7.6±4.2 WU and mixed venous oxygen saturation 61±8%. Patients 
undergoing surgery were younger, more likely to be male and had fewer comorbidities (table 
19). 
The imaging investigations that patients underwent are shown in table 20. CTPA was the most 
common investigation performed in 488 (96%) of patients followed by 3D MR perfusion/MR 
angiography 424 (84%), ventilation and perfusion/perfusion-only imaging 396 (78%). 
Conventional pulmonary angiography was performed in only 9 (2%) patients. Multimodality 
imaging was performed in 98% of patients undergoing pulmonary endarterectomy and 94% of 
patients not undergoing surgery. 82% of the patients identified in this study were diagnosed 
with technically operable disease based on the non-invasive multimodality imaging approach. 
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At census end date 256 patients had undergone pulmonary endarterectomy and 251 had not 
undergone surgery due to disease distribution, comorbidities or patient choice. Of those 
undergoing pulmonary endarterectomy the perioperative mortality was 3% with survival of 90% 
at 3 years and 85% at 5 years (figure 20). Survival in the CTEPH-not-operated group at three 
and five years was 70% and 55% respectively (figure 20).  
Discussion 
To my knowledge, this is the largest study to examine the use of a first-line non-invasive 
multimodality imaging approach alongside right heart catheterisation in CTEPH diagnosis and 
treatment assessment. This study demonstrates that this approach can accurately identify 
patients with technically operable disease with a low perioperative mortality and excellent long-
term survival following surgery, comparable to patients undergoing conventional pulmonary 
angiography as reported in contemporary published literature.   
82% of the patients in this study were deemed to have technically operable disease, which 
was similar to the data from the International CTEPH registry (where 80% of the patients were 
deemed to have technically operable disease) suggesting that similar proportions of patients 
can be identified as technically operable CTEPH by using a non-invasive multimodality 
imaging approach as compared to conventional pulmonary angiography (Pepke-Zaba et al., 
2011, Delcroix et al., 2016). 
Pulmonary endarterectomy is the treatment of choice in patients with CTEPH (Galie et al., 
2015). It offers the best prospect of improved quality and quantity of life and identification of 
such patients is therefore paramount. I observed excellent long-term outcomes (3-year survival 
90%) and low perioperative mortality (3%). These findings are comparable with multiple 
previous multicentre registries including the International CTEPH Registry (Delcroix et al., 
2016), the Spanish Registry (Escribano-Subias et al., 2016) and the UK Pulmonary 
Hypertension Registry  (Condliffe et al., 2008). Specifically, the international CTEPH registry, 
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which is the largest such registry of its kind reported a peri-operative mortality of 4.7% and a 3-
year survival from diagnosis of 89%, with at least 63% of patients undergoing conventional 
pulmonary angiography (Pepke-Zaba et al., 2011, Delcroix et al., 2016). Demographic and 
haemodynamic characteristics and rates of previous venous thromboembolic disease were 
also comparable to the international CTEPH registry (Pepke-Zaba et al., 2011), suggesting 
that similar populations can be identified using low rates of conventional angiography. 
Although conventional pulmonary angiography may be required in the small proportion of 
patients who are candidates for balloon pulmonary angioplasty, a first-line non-invasive 
approach to identify and classify CTEPH can significantly reduce the need for an invasive 
procedure with its associated risks. The recently published Fleischner statement on pulmonary 
hypertension has highlighted the value of a multi-modality imaging approach in the 
assessment of CTEPH and the value of alternative techniques to conventional pulmonary 
angiography (Remy-Jardin et al., 2021). 
Limitations 
This is a single centre retrospective study assessing outcomes from a non-invasive 
multimodality imaging strategy in patients with CTEPH and therefore would benefit from 
external validation. Nonetheless, the outcomes chosen (identification of surgical disease and 
peri-operative mortality) and the consecutive nature of enrolment of patients with CTEPH 
provides a basis for further study of such a non-invasive approach. Recent expert opinion 
(Remy-Jardin et al., 2021) and statements from the European Respiratory Society (Delcroix et 








In summary, this study demonstrates that a multi-modality non-invasive imaging approach can 
be used to identify patients with technically operable disease with similar outcomes following 
surgery as compared to patients undergoing conventional pulmonary angiography. This study 
therefore provides an alternative to strategies utilising conventional pulmonary angiography in 


















Table 19: Baseline characteristics of patients with CTEPH (operated vs not operated groups) 
  CTEPH (whole-
cohort) 
(n = 507) 
CTEPH-operated 
(n = 256) 
CTEPH-not -
operated 
(n = 251) 
p-value 
Age (years) 63 (15) 58 (15) 68 (14) <0.001 
Gender (%, Female) 49% 44% 54% 0.019 
BMI (kg.m-2) 29 (7) 30 (7) 29 (7) 0.471 
WHO FC (I/II vs III/IV) % 11/89 14/87 9/91 0.138 
ISWD (m) 195 (181) 235 (188) 154 (163) <0.001 
RAP (mmHg) 11 (5) 11 (6) 11 (5) 0.828 
mPAP (mmHg) 46 (11) 47 (11) 45 (11) 0.139 
CI (L.min.m-2) 2.6 (0.7) 2.6 (0.7) 2.6 (0.8) 0.275 
PAWP (mmHg) 12 (5) 12 (4) 12 (5) 0.478 
PVR  (WU) 7.6 (4.2) 7.7 (4.1) 7.5 (4.3) 0.668 
SvO2 (%) 61 (8) 61 (8) 62 (9) 0.574 
FEV1 (% predicted) 80 (36) 84 (45) 77 (23) 0.043 
DLCO (% predicted) 61 (17) 65 (15) 57 (18) <0.001 
Previous acute VTE (%) 72 75 70 0.184 
Cancer (%) 11 6 16 0.001 
CAD (%) 11 11 12 0.826 
COPD (%) 20 14 27 <0.001 
LV dysfunction (%) 5 2 7 0.017 
CKD (%) 7 3 10 0.001 
Obesity (%) 36 39 32 0.091 
 
Definition of abbreviations: n = number of patients; BMI = body mass index; WHO FC = World Health Organization functional class; ISWD = 
incremental shuttle walk distance; RAP = right atrial pressure; mPAP = mean pulmonary arterial pressure; CI = cardiac index; PCWP = 
pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; SvO2  = mixed venous oxygen saturation; FEV1 = forced 
expiratory volume in one second; DLCO = diffusion capacity  of lung for carbon monoxide; VTE = venous thromboembolism; PE = pulmonary 
embolism; CAD = coronary artery disease; LV = left ventricle; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; 
PH = pulmonary hypertension;  
Values are mean (standard deviation) or percentage unless otherwise indicated. Mean. 















(n = 256) 
CTEPH 
not operated 
(n = 251) 
CTPA, Perfusion MRA, Scintigram 334 (68%) 185(72%) 159 (63%) 
CTPA, Perfusion MRA 74 (15%) 34 (13%) 40 (16%) 
CTPA, Scintigram 53 (10%) 20 (8%) 33 (13%) 
CTPA only 18 (4%) 4 (2%) 14 (6%) 
Perfusion MRA, Scintigram 8 (2%) 5 (2%) 3 (1%) 
CTPA, Perfusion MRA, DSA 8 (2%) 7 (3%) 2 (1%) 
CTPA, Scintigram, DSA   1(0.2%)   1 (0.5%) 0 (0%) 
DSA only 0 (0%) 0 (0%) 0 (0%) 
Scintigram only 0 (0%) 0 (0%) 0 (0%) 
 
Definition of abbreviations: n = number of patients; CTPA = computed tomographic pulmonary angiogram; Perfusion MRA = 3D magnetic 
resonance perfusion map and magnetic resonance angiogram; DSA = digital subtraction angiography (conventional pulmonary angiogram); 
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Figure 20: Kaplan-Meier estimates of survival from date of diagnosis comparing outcomes in 
CTEPH operated and not operated patients 
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In this thesis I have described the baseline characteristics, the long-term survival rates, and 
identified prognostic indicators in patients with newly diagnosed CTEPH with a focus on 
patients with technically operable disease who have not undergone surgery and have explored 
associations. Data from my thesis has shown that CTEPH includes a wide spectrum of 
disease which impacts on long-term survival. I have confirmed that patients with CTEPH who 
have technically operable disease and are judged to be candidates for surgery have an 
excellent long-term survival following PEA. Importantly, I have shown for the first time that in a 
large cohort of patients with CTEPH the long-term survival of patients undergoing surgery is 
superior to patients who were offered but declined surgery. I have also identified several 
factors that may aid clinical decision making and help stratify patients who are potential 
candidates for surgery into higher or lower risk of mortality groups.  
The data in this thesis has shown an increase in the number of patients diagnosed with 
CTEPH annually at the study unit over the last decade, with diagnostic rates now in excess of 
5/million/year. It is not entirely clear as to the cause of the increased diagnostic rates, 
however, it is likely that this reflects an increased awareness amongst healthcare 
professionals of CTEPH coupled with the more recent availability of effective therapies. It will 
of course be interesting to assess in the coming years whether more aggressive approaches 
to long-term anticoagulation that reflect improved stratification of those at highest and lowest 
risk of recurrent thromboembolic disease may reduce the burden of CTEPH. In the interim, 
approaches to raise awareness and to develop specific clinics for the follow-up of patients 
following an acute pulmonary embolism may aid improved identification of patients with 
CTEPH (De-Fonseka D, 2014). Deployment of such clinics in Sheffield has achieved 
diagnostic rates in excess of 10/million/ year, more than double diagnostic rates in areas 
where there is no dedicated follow-up of patients following pulmonary embolism.  
My main finding in this study is the superior survival of patients with CTEPH who underwent 
surgery compared to patients who were eligible for surgery but turned it down. Patients who 
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declined surgery were more likely to be female, 10 years older and had more co-morbidities 
compared to patients who underwent surgery which does put them at a higher risk of post-
surgical mortality. Nonetheless, following multivariate analyses when important prognostic 
markers were taken into account the decision to decline surgery remained an important 
independent predictor of a worse outcome. The proportion of patients who declined surgery 
was much higher in my study compared to other registries including the international CTEPH 
registry but in line with the data from the National PEA centre at the Royal Papworth Hospital 
at Cambridge where data from consecutive patients with CTEPH was also collected. This can 
be explained by one of the limitations of the International CTEPH Registry which was the 
selected nature of patient enrolment. This had likely enriched this population for patients 
undergoing surgery. Very importantly, given that the survival of patients who undergo surgery 
is vastly superior to those who were offered surgery but declined, this study highlights the 
importance of how we provide information and counsel patients. One outcome from this study 
is a recognition of the need to explore factors underpinning decision making and whether there 
are additional tools that may aid this decision-making process. Extra counselling of patients 
who decline surgery (whilst respecting the patient’s wishes) may give them more time and 
opportunity to improve rapport and trust with the treating healthcare professionals. This might 
also help them accept the difficult realities of life to and come to a truly fully informed decision. 
In this thesis I have also identified prognostic indicators (DLCO of 62%, RAP of 11mmg Hg and 
SvO2 of 62%) with excellent negative predictive values in patients who have declined surgery. 
This may help in counselling patients and aid in clinical decision making. Being able to stratify 
patients into poor short and medium-term outcome groups based on these prognostic 
indicators may be helpful in counselling strategies. In patients who are identified at low-risk of 
short and medium-term mortality, particularly older patients who decline surgery, this may 
provide reassurance that not having the surgical intervention may not impact them 
prognostically, although it would be expected to benefit them symptomatically. Whereas in 
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patients who have adverse prognostic indicators they may be more inclined to consider a 
surgical intervention.  
One of the unexpected findings of this study was that women were more likely to decline 
surgery than men. Interestingly, there is data in the literature including from the gambling 
industry, on the impact of sex on risk taking. How patients are counselled and whether the sex 
or gender of the patient influences this is not explored by this study. However, as a follow-on 
from this thesis a study can be proposed that explores in patients with CTEPH the factors that 
influence their decision-making around treatment. This proposal includes conducting a 
qualitative and quantitative survey of patients and their families who accepted or declined 
surgery. In addition, there is also a plan to interview medical staff including pulmonary vascular 
physicians, PEA surgeons and specialist nurses. Discussions are currently on-going with 
stakeholders including with the UK patient charity (PHA-UK) and the University of Manchester 
to take this work forward. Finally, with respect to surgery, this study provides further data 
supporting the prognostic value of PEA for CTEPH. In the multivariate analysis I found that 
having PEA was one of the strongest predictors of survival in patients with CTEPH. A 
randomized control trial (RCT) randomising patients with CTEPH and operable disease to 
surgery or medical therapy would provide the highest level of evidence but given the 
overwhelming data conducting such a study would be considered unethical.   
In this thesis I was also able to demonstrate in a large cohort of patients with CTEPH that a 
non-invasive multimodality imaging approach can be used alongside right heart catheterisation 
to diagnose patients with technically operable disease with outcomes and the proportions of 
patients undergoing surgery similar to other reports in contemporaneous registries. Thus, it 
offers an alternative to the guidelines from 2015 regarding imaging approaches in the 
diagnosis of the disease.  
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The main weakness in this study was the absence of a comparator group (patients undergoing 
conventional pulmonary angiogram) and lack of access to raw data from other registries 
(including the International CTEPH registry). When they are widely available in clinical 
practice, newer imaging techniques such as cone beam CT and dual energy CT could 
potentially replace conventional pulmonary angiogram (CPA) in the future to study the distal 
pulmonary vasculature. Although a non-invasive approach may be helpful when deciding on 
whether patients are candidates for surgery the advent of balloon pulmonary angioplasty 
means that conventional pulmonary angiography will remain an important part of the 
assessment of selected patients with CTEPH who are not considered surgical candidates and 
cases where non-invasive imaging is non-diagnostic. Importantly, the multimodality imaging 
approach highlighted in this thesis has been recognised as an important part of the 
assessment of patients with CTEPH by a recently published report form the Fleischner Society 
(Remy-Jardin et al., 2021). 
Over the last 20 years the treatment of CTEPH has evolved and there has been a recent move 
to combine treatment modalities. There is also an increasing interest in lowering the risk of 
mortality by reducing pulmonary vascular resistance either prior to surgery or balloon 
pulmonary angioplasty. In this thesis I found that majority of the patients were treated with 
sildenafil as a bridge to surgery and pre-treatment was not associated with a worse outcome 
as has been highlighted in the International CTEPH Registry. It is possible that the higher 
mortality in the International CTEPH Registry in patients treated with drug therapy may have 
been related to delaying or reducing access to surgery. Survival following surgery was similar 
in this study and the international CTEPH registry. I also showed that time to surgery was not a 
prognostic indicator for the population as a whole. Several RCTs are currently underway which 
are looking at the role of riociguat as a single agent as a bridge to surgery. Interestingly, 
despite the off-label use of sildenafil in CTEPH and small studies previously performed in 
single centres there is no multicentre RCT data for sildenafil as a treatment for CTEPH. 
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One of the challenges during my thesis was related to collection of data. I encountered 
significant delays due to my ambitions to build a user-friendly database that could be used to 
prospectively enter data of patients after the completion of my study. It took a considerable 
amount of my research time to create the data collection software. In addition, I faced multiple 
challenges including information governance issues. Despite investing significant amounts of 
time and efforts seeking a local in-house solution none was forthcoming. On reflection it may 
have been a missed opportunity not to have contacted the International CTEPH registry to 
have asked for permission to use their web-based data collection software.  
Furthermore, one of my ambitions had been to consider whether the assessment of patients 
with CTEPH could be done entirely non-invasively and without the need for right heart 
catheterization. However, right heart catheterization remains the gold standard for the 
assessment of pressure and PVR, the latter a well validated tool aiding the selection of 
patients for surgery. Whether, such estimates of PVR and pressure could be made non-
invasively requires further study although the database and imaging warehouse that I have 
helped establish may allow a subsequent colleague to explore this potential area of research, 
particularly in exploring the use of non-invasive imaging to assess haemodynamic severity and 
to assess whether incorporating AI techniques can more accurately predict peri-operative 
mortality.  
Another one of the big changes that occurred during the conduction of my thesis has been the 
development of BPA as a treatment of CTEPH and the licensing of riociguat as a treatment for 
non-surgical CTEPH in subsequent years. In this thesis no patients underwent BPA or 
received treatment with riociguat, as these treatment options were not available during that 
time. These are now standard treatment options for patients with non-operable CTEPH in the 
UK. RCT’s comparing riociguat versus BPA in patients with distal disease are underway as are 
clinical trials of multimodality approaches to the treatment of CTEPH.  Nonetheless I do feel 
that my contribution to this rapidly evolving field has been significant by providing important 
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information that can guide patients with respect to decision making regarding PEA. One of the 
weaknesses of this study was its single centre nature. However, a recent publication from the 
large multicentre COMPERA Registry has confirmed my findings with respect to the negative 
impact of declining surgery on outcome in CTEPH. 
In conclusion, this thesis highlights that more work needs to be undertaken to understand the 
reasons why patients with CTEPH who are offered surgery decline to undergo the procedure. 
Which factors in particular motivate patients, whether there are differences in how physicians 
and surgeons counsel patients and what specific counselling approaches may benefit 
particular groups of patients are the questions that need exploring. By highlighting these areas 
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Table S1: The table shows all the fields that are present in the new ASPIRE 2 registry 
database but missing in the ASPIRE 1 registry database 
Number Categories Sub-categories 
   
1 First clinic visit Emphasis 10 QoL questionnaire (Y/N) 
  Emphasis 10 QoL questionnaire Score (0-50) 
   
2 Final clinic visit Emphasis 10 QoL questionnaire (Y/N) 
  Emphasis 10 QoL questionnaire Score (0-50) 
   
3 Presenting symptoms Duration of symptoms 
  Shortness of breath (Y/N) 
  Chest pain (Y/N) 
  Palpitations (Y/N) 
  Presyncope (Y/N) 
  Syncope (Y/N) 
  Cough (Y/N) 
  Haemoptysis (Y/N) 
 
 Ankle swelling (Y/N) 
 Calf pain (Y/N) 
Tiredness (Y/N) 
others 
   
4 Risk factors for CTEPH History of DVT and PE (Y/N) 
  History of IVC filter insertion for PE (Y/N) 
  Previous major surgery (Y/N) 
  Varicose vein (Y/N) 
  Obesity (Y/N) 
  Chronic venous insufficiency (Y/N) 
  Prolonged immobilization (Y/N) 
  Chronic osteomyelitis (Y/N) 
  History of cancer (Y/N)  
  Coronary artery disease (Y/N) 
  Thyroid disorder (Y/N) 
  History of fracture (Y/N) 
  NIDDM (Y/N) 
  IDDM (Y/N) 
  CCF(Y/N) 
  History of infected VA shunt/PPM (Y/N) 
   
5 Imaging modalities Q-scan(Y/N) 
  Date of Q-scan 
  VQ Scan (Y/N) 
  Date of VQ scan 
  CTPA (Y/N) 
  Date of CTPA 
  MRA with perfusion mapping (Y/N) 
  Date of test 
  Formal pulmonary angiography (Y/N) 




















Date of test 
Result 
   
7 Pulmonary function test (first) FEV1/FVC 
   
8 Pulmonary function test (final) FEV1/FVC 
   
9 Right heart catheter (first) TPR 
   
10 Right heart catheter (final) TPR 
   
11 Cardiac MRI (first) C-MRI (Y/N) 
  Date of C-MRI 
  Size of aorta 
  PA size 
  LVEDV 
  LVEF (%) 
  LVEDVI 
  LVESVI 
  SV 
  SVI 
  HR 
  CO 
  CI 
  RVEDV 
  RVESV 
  RVEF (%) 
  RVEDVI 
  RVESVI 
   
12 Cardiac MRI (final) C- MRI (Y/N) 
  Date of C-MRI 
  Size of aorta 
  PA size 
  LVEDV 
  LVEF (%) 
  LVEDVI 
  LVESVI 
  SV 
  SVI 
  HR 
  CO 
  CI 
  RVEDV 
  RVESV 
  RVEF (%) 
  RVEDVI 
  RVESVI 
   
13 Pulmonary endarterectomy Date of referral for PEA surgery 
127 
 
Number Categories Sub-categories 
14 IVC filter insertion Date of IVC filter insertion 
   












   
16 Final diagnosis CTEPH-surgical-operated 
  CTEPH-surgical-not operated 
  CTEPH-non-surgical 
  CTED 
 
Definition of abbreviation: QoL= quality of life; DVT= deep vein thrombosis; PE= pulmonary embolism; IVC=inferior vena cava; NIDDM= non-
insulin dependent diabetes mellitus; IDDM= insulin dependent diabetes mellitus; CCF= congestive cardiac failure; Q=perfusion; VQ= 
ventilation perfusion; CTPA=computed tomography pulmonary angiogram; MRA= magnetic resonance angiogram; CRP= C reactive protein; 
FEV1=forced expiratory volume at 1st second; FVC= forced vital capacity; TPR= total pulmonary resistance; C-MRI= cardiac magnetic 
resonance imaging; PA=pulmonary artery; LVEDV= left ventricular end diastolic volume; LVEF=left ventricular ejection fraction; LVEDVI=left 
ventricular end diastolic volume index; LVESVI=left ventricular end systolic volume index; SV=stroke volume; SVI=stroke volume index; 
HR=heart rate; CO=cardiac output; CI=cardiac index; RVEDV=right ventricular end diastolic volume; RVESV=right ventricular end systolic 
volume; RVEF= right ventricular ejection fraction; RVEDVI= right ventricular end diastolic volume index; RVESVI= right ventricular end systolic 
volume index; PEA= pulmonary endarterectomy; CTEPH= chronic thromboembolic pulmonary hypertension; CTED= chronic thromboembolic 



















Table S2: The following variables were used in the cox regression analysis for survival during 
univariate analysis in the CTEPH-whole cohort, CTEPH-surgical-operated, CTEPH-surgical-
not-operated (including unfit for surgery and patient choice) and CTEPH-non-surgical-disease 
distribution groups 
Age History of fracture Serum Creatinine 
Gender Hypertension Serum Albumin 
History of VTE History of smoking White blood cells 
History of thrombolysis for PE Family history of VTE Neutrophil 
Thrombophilic disorders Duration of symptoms Platelets 
Antiphospholipid syndrome Syncope C-reactive protein 
History of splenectomy Ankle swelling mPAP 
History of IBD Chest pain Change in mPAP 
History of infected AV shunt/PPM Palpitation Right atrial pressure 
Obesity Presyncope Cardiac output 
IDDM Haemoptysis Cardiac index 
NIDDM WHO FC (first) Pulmonary vascular resistance 
History of cancer Saturation (first) Total pulmonary resistance 
Chronic venous insufficiency Systolic Blood pressure (first) SvO2 
History of Coronary artery disease Body mass index LVEF (%)-first 
Left ventricular failure ISWD (first) RVEF (%) -first 
Chronic kidney disease ISWD (final) PH specific targeted therapy 
History of bronchiectasis Change in walk distance Intravenous iloprost 
History of asthma FEV1(%)- first Subcutaneous LMWH 
Chronic obstructive pulmonary 
disease 
FVC (%)-first PEA surgery (for CTEPH-whole 
cohort only) 
Interstitial lung disease FEV1/FVC-first Post-operative PVR (for CTEPH-
surgical-operated only) 
Sleep disordered breathing DLCO (%)-first 
Persistent PH post PEA (for 
CTEPH-surgical-operated) 
Cerebrovascular event DLCO (%)-final Bridging therapy (for CTEPH-
surgical-operated only) 
Dyslipidaemia Haemoglobin  
History of Valvular heart disease Serum Ferritin  
 
Definition of abbreviations; VTE = venous thromboembolism; PE = pulmonary embolism; IBD = inflammatory bowel disease; AV = atrio-
ventricular; PPM = permanent pacemaker; IDDM = insulin dependent diabetes mellitus; NIDDM = non-insulin dependent diabetes mellitus; 
WHO FC = World Health Organisation functional class; ISWD = incremental shuttle walk distance; FEV1 = forced expiratory volume at 1st 
second; FVC = forced vital capacity; DLCO = diffusion capacity of lung for carbon monoxide;  mPAP = mean pulmonary artery pressure; SvO2 = 
mixed venous oxygen saturation; LVEF = left ventricular ejection fraction; RVEF = right ventricular ejection fraction; PH = pulmonary 
hypertension; PEA = pulmonary endarterectomy; CTEPH = chronic thromboembolic pulmonary hypertension; PVR = pulmonary vascular 























































































Figure S12: ASPIRE registry showing the final diagnosis 
 
